预约演示
更新于：2025-11-26
Obinutuzumab
奥妥珠单抗
更新于：2025-11-26
概要
基本信息
药物类型 单克隆抗体 |
别名 Afutuzumab、Anti-CD20 monoclonal antibody R7159、Gazyvaro + [22] |
靶点 |
作用方式 抑制剂 |
作用机制 CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 68713L
来源: *****
Sequence Code 9699891H
来源: *****
关联
333
项与 奥妥珠单抗 相关的临床试验NCT07233330
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a Fully Academic, Single-arm, Open, Prospective, Intervention Trial
This is a multicenter, open-label, single-arm Phase II clinical trial designed to evaluate the safety, efficacy, and immunological effects of obinutuzumab in adult patients with multi-relapsing, rituximab-dependent steroid-sensitive NS.
Obinutuzumab is a glycoengineered, humanized type II anti-CD20 monoclonal antibody that was initially developed to overcome rituximab resistance in B-cell malignancies. Obinutuzumab induced a longer and deeper B cell depletion than rituximab being able to deplete B cells in lymphoid tissue other than peripheral blood, as shown in both animal models and patients with chronic lymphocytic leukemia or kidney transplantation. Notably, obinutuzumab was found to be more efficient than rituximab in inducing B-cell cytotoxicity in-vitro, especially on naïve (IgD+CD27-) and switched (IgD-CD27+) memory B cells. This is a clinically relevant finding, because memory B cells are known to be associated with the risk of relapse after rituximab treatment in children with nephrotic syndrome. A recent retrospective study in 41 children [median (IQR) age: 10.6 (8.5-14.29) years] with steroid-dependent or frequently relapsing nephrotic syndrome, showed that treatment with obinutuzumab achieved B-cell depletion and sustained remission in 38 (93%) and 28 (68%) children at 12 and 24 months after treatment, respectively. Treatment was safe and well tolerated. Moreover, preliminary data indicate that obinutuzumab treatment can achieve complete or partial remission of the nephrotic syndrome in the large majority of adult participants with membranous nephropathy refractory to different immunosuppressive medications including rituximab, and even the human type 1 anti-CD20 antibody ofatumumab or the anti-CD38 antibody felzartamab (NCT05050214). Notably, obinutuzumab treatment achieved B-cell depletion and proteinuria reduction in all treated participants and persistent circulating anti-PLA2R antibody depletion in all participants with PLA2R-related disease even during the recovery of circulating B cells (NCT05050214). Conceivably, obinutuzumab could achieve remission of idiopathic nephrotic syndrome by inducing profound and sustained B-cell depletion, thereby inhibiting the production of anti-podocyte autoantibodies or the production of still unknown B-cell derived nephritogenic mediators and autoantibodies.
Thus, whether obinutuzumab treatment may achieve persistent remission also in adult participants with multi-relapsing, rituximab-dependent nephrotic syndrome, as previously reported in children, and as already observed in adult participants with refractory membranous nephropathy (NCT05050214), and whether this effect is associated with delayed recovery of switched memory B cells and emergence of B cells with a naïve phenotype as well as sustained reduction or depletion of circulating anti-podocyte antibodies is worth investigating.
In parallel to the evaluation of the phenotype of repopulating B cells, we will evaluate serum levels of the B-cell activating factor (BAFF). BAFF is a cytokine that orchestrates peripheral tolerance of B cells and promotes the survival of autoreactive B cells escaping central tolerance mechanisms. In participants with autoimmune diseases, such as systemic lupus erythematosus or rheumatoid arthritis, the relapse of disease activity after rituximab treatment has been associated with compensatory elevation of the B cell-activating factor BAFF levels. Elevated BAFF levels at baseline or during the follow-up may explain the resistance or dependency to anti-CD20 depleting antibodies in participants with idiopathic nephrotic syndrome.
Obinutuzumab is a glycoengineered, humanized type II anti-CD20 monoclonal antibody that was initially developed to overcome rituximab resistance in B-cell malignancies. Obinutuzumab induced a longer and deeper B cell depletion than rituximab being able to deplete B cells in lymphoid tissue other than peripheral blood, as shown in both animal models and patients with chronic lymphocytic leukemia or kidney transplantation. Notably, obinutuzumab was found to be more efficient than rituximab in inducing B-cell cytotoxicity in-vitro, especially on naïve (IgD+CD27-) and switched (IgD-CD27+) memory B cells. This is a clinically relevant finding, because memory B cells are known to be associated with the risk of relapse after rituximab treatment in children with nephrotic syndrome. A recent retrospective study in 41 children [median (IQR) age: 10.6 (8.5-14.29) years] with steroid-dependent or frequently relapsing nephrotic syndrome, showed that treatment with obinutuzumab achieved B-cell depletion and sustained remission in 38 (93%) and 28 (68%) children at 12 and 24 months after treatment, respectively. Treatment was safe and well tolerated. Moreover, preliminary data indicate that obinutuzumab treatment can achieve complete or partial remission of the nephrotic syndrome in the large majority of adult participants with membranous nephropathy refractory to different immunosuppressive medications including rituximab, and even the human type 1 anti-CD20 antibody ofatumumab or the anti-CD38 antibody felzartamab (NCT05050214). Notably, obinutuzumab treatment achieved B-cell depletion and proteinuria reduction in all treated participants and persistent circulating anti-PLA2R antibody depletion in all participants with PLA2R-related disease even during the recovery of circulating B cells (NCT05050214). Conceivably, obinutuzumab could achieve remission of idiopathic nephrotic syndrome by inducing profound and sustained B-cell depletion, thereby inhibiting the production of anti-podocyte autoantibodies or the production of still unknown B-cell derived nephritogenic mediators and autoantibodies.
Thus, whether obinutuzumab treatment may achieve persistent remission also in adult participants with multi-relapsing, rituximab-dependent nephrotic syndrome, as previously reported in children, and as already observed in adult participants with refractory membranous nephropathy (NCT05050214), and whether this effect is associated with delayed recovery of switched memory B cells and emergence of B cells with a naïve phenotype as well as sustained reduction or depletion of circulating anti-podocyte antibodies is worth investigating.
In parallel to the evaluation of the phenotype of repopulating B cells, we will evaluate serum levels of the B-cell activating factor (BAFF). BAFF is a cytokine that orchestrates peripheral tolerance of B cells and promotes the survival of autoreactive B cells escaping central tolerance mechanisms. In participants with autoimmune diseases, such as systemic lupus erythematosus or rheumatoid arthritis, the relapse of disease activity after rituximab treatment has been associated with compensatory elevation of the B cell-activating factor BAFF levels. Elevated BAFF levels at baseline or during the follow-up may explain the resistance or dependency to anti-CD20 depleting antibodies in participants with idiopathic nephrotic syndrome.
开始日期2026-02-01 |
ChiCTR2500113199
Zanubrutinib Combined with Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in Treatment-Naive Waldenström's Macroglobulinemia: A Phase II Clinical Study
开始日期2025-12-25 |
申办/合作机构 |
NCT07218510
A Phase 2 Study of Venetoclax + Obinutuzumab Followed by Epcoritamab in Previously Untreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (LonGEVity)
This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Epcoritamab, a bispecific monoclonal antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. The combination of venetoclax and obinutuzumab is a standard treatment for CLL/SLL and has been found to be safe and effective. Adding epcoritamab to standard treatment with venetoclax and obinutuzumab may lead to deeper and longer-lasting responses in patients with untreated CLL/SLL.
开始日期2025-12-09 |
申办/合作机构 |
100 项与 奥妥珠单抗 相关的临床结果
登录后查看更多信息
100 项与 奥妥珠单抗 相关的转化医学
登录后查看更多信息
100 项与 奥妥珠单抗 相关的专利（医药）
登录后查看更多信息
1,141
项与 奥妥珠单抗 相关的文献（医药）2026-01-01·CHEMICO-BIOLOGICAL INTERACTIONS
Platinum(IV) oxaliplatin analog containing axial benzoate ligands induces mitochondrial hyperpolarization and caspase-dependent apoptosis in pancreatic cancer cell models
Article
作者: Brabec, Viktor ; Berecka, Michal ; Ditaranto, Nicoletta ; Pracharova, Jitka ; Margiotta, Nicola ; Kasparkova, Jana ; Barbanente, Alessandra
This study investigates the molecular mechanisms underlying the antiproliferative effects of the platinum(IV) complex trans-[Pt(OBz)2(O,C-10-BzODA)(1R,2R-DACH)] (complex 1; OBz = benzoate, 10-BzODA = 10-benzoyloxy-2-decenoate, DACH = diaminocyclohexane) in pancreatic cancer cell models. Initial findings revealed that complex 1 exhibits substantial antiproliferative activity, positioning it as a promising therapeutic agent for pancreatic cancer, where effective treatment options remain limited. Notably, complex 1 demonstrates significantly greater efficacy compared to platinum(II) drugs, such as cisplatin and oxaliplatin, with IC50 values in the low micromolar range across various pancreatic cancer cell lines. Mechanistic studies suggest that complex 1's enhanced activity is attributed to the axial benzoate ligands, which differentiate it from its platinum(II) analog. Complex 1 accumulates intracellular platinum without undergoing reduction in the extracellular environment, and it induces mitochondrial hyperpolarization. This effect is reminiscent of free sodium benzoate but occurs at a much lower extracellular concentration, indicating the crucial role of the benzoate ligands in modulating mitochondrial function. Furthermore, complex 1 triggers caspase-dependent apoptosis in cancer cells and is also effective in 3D tumor cell models, highlighting its potential as an effective anticancer agent. Thus, this work presents a Pt(IV) prodrug bearing benzoate axial ligands that exhibit distinctive chemical and biological behavior compared with previously reported Pt(IV) prodrugs. In conclusion, the unique properties of complex 1, driven by its benzoate ligands, suggest that Pt(IV) complexes represent a promising approach for the development of targeted chemotherapeutic agents for the treatment of pancreatic cancer.
2025-12-01·Blood Research
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors
Article
作者: Yoon, Sang Eun ; Choi, Yunsuk ; Park, Hyunkyung ; Kim, Seok Jin ; Park, Han-Seung ; Lee, Jung-Hee ; Hur, Joon Young ; Won, Young-Woong ; Choi, Jung Hye ; Lee, Je-Hwan ; Kim, Won Seog
Abstract:
Purpose:
Bruton tyrosine kinase inhibitors (BTKis) are effective and well-tolerated treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Here, we describe the clinical characteristics of hepatitis B virus (HBV) reactivation in patients with hematological malignancies treated with BTKis.
Methods:
Patients were required to have a pathologically confirmed diagnosis of CLL or MCL, receive at least one cycle of ibrutinib or zanubrutinib, and have either positive hepatitis B surface antigen or hepatitis B core antibody at diagnosis. Patients were excluded if they had received rituximab or obinutuzumab within the previous 12 months.
Results:
We identified five patients with CLL and one with MCL who had resolved HBV infections and received BTKis during the study period. None of the patients received anti-HBV prophylaxis after CLL diagnosis. The patient with MCL who received zanubrutinib was confirmed to have HBV reactivation even after prophylactic entecavir administration followed by tenofovir. All five patients with CLL received ibrutinib as second-line therapy. A 62-year-old man died of hepatorenal syndrome associated with HBV reactivation despite entecavir treatment.
Conclusion:
To the best of our knowledge, this is the first description of HBV-related death in patients receiving BTKis from HBV-endemic areas, and the first case of HBV reactivation associated with zanubrutinib despite previous entecavir prophylaxis. Further prospective studies are warranted to develop useful guidelines for monitoring HBV DNA and antiviral prophylaxis to prevent HBV reactivation after BTKi therapy.
2025-11-13·BLOOD
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
Article
作者: Fink, Anna ; Tadmor, Tamar ; Kreuzer, Karl-Anton ; Robrecht, Sandra ; Simon, Florian ; Giza, Adam ; Schwarer, Anthony P ; Schneider, Christof ; Fürstenau, Moritz ; Kilfoyle, Allanah ; Illmer, Thomas ; Eichhorst, Barbara F ; Strumberg, Dirk ; Ritgen, Matthias ; Gregor, Michael ; Wendtner, Clemens-Martin ; Tausch, Eugen ; Loscertales, Javier ; Juliusson, Gunnar ; Sivcheva, Liliya ; Thornton, Patrick ; Al-Sawaf, Othman ; Niemann, Carsten Utoft ; Hallek, Michael J ; Weinkove, Robert ; Kater, Arnon P ; Levin, Mark-David ; Staber, Philipp B ; Janssens, Ann ; Lindstrom, Vesa ; Fischer, Kirsten ; Stilgenbauer, Stephan ; von Tresckow, Julia ; da Cunha-Bang, Caspar
Abstract:
Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 trials, excluding patients with TP53 aberrations. Fitness was assessed using the cumulative illness rating scale (CIRS, >6) and creatinine clearance (≤70 mL/min). Among 410 patients (median age, 67 years), 55.7% were unfit (median age, 72 years) and 44.3% were fit (median age, 58 years). Overall response rate (ORR) was 89.5% in unfit and 96.1% in fit patients. Rates of undetectable minimal residual disease (uMRD) at <10–4 were 80.3% in unfit and 85.1% in fit patients. Progression-free survival (PFS) at 3 years was 86.4% vs 87.5% (hazard ratio, [HR], 1.12; 95% confidence interval [CI], 0.70-1.81; P = .63). Overall survival at 3 years was 91.8% vs 96.9% (HR, 2.02; 95% CI, 0.90-4.55; P = .088). Adverse events included neutropenia (62.7% unfit, 56.9% fit), infusion-related-reactions (44.3% unfit, 56.9% fit), fatigue (15.8% unfit, 35.9% fit), and infections (57.5% unfit, 69.6% fit). Venetoclax dose reductions of <80% occurred in 39.6% of unfit and 17.6% of fit patients, with lower ORR (83.3% vs 98.2%) and uMRD rates (74.2% vs 87.9%) in those with reduced dose intensities, but similar PFS. Dose reductions of <70% were associated with shorter PFS. Overall, this study shows comparable efficacy and toxicity of Ven-Obi in fit and unfit patients with CLL.
687
项与 奥妥珠单抗 相关的新闻（医药）2025-11-24
Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses1,2
Lunsumio subcutaneous offers a new treatment option that can significantly reduce administration time to approximately one minute
Availability of Lunsumio SC allows patients to receive treatment aligned to clinical requirements and lifestyle preferences
19 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional marketing authorisation of Lunsumio® (mosunetuzumab) subcutaneous (SC) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. Approval is based on results from the phase I/II GO29781 study, which showed that Lunsumio SC had pharmacokinetic non-inferiority compared with intravenous (IV) administration, with no unexpected safety signals.3
“Building on the benefits of its fixed-duration dosing schedule, Lunsumio can now be administered with a one-minute subcutaneous injection, providing people with relapsed or refractory follicular lymphoma an additional treatment option to help meet their individual clinical requirements and lifestyle preferences,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Developing new formulations of our medicines is part of our commitment to offering greater flexibility and a better treatment experience for patients.”
Lunsumio SC is a fixed-duration treatment that can be initiated in the outpatient setting and has the potential to substantially reduce treatment administration time with an approximately one-minute injection, compared with a 2-4 hour IV infusion.
Lunsumio has shown a favourable benefit-risk profile and high rates of deep and durable remissions with both IV and SC administration routes in third-line or later (3L+) FL.1,4 Lunsumio IV was the first bispecific antibody approved for 3L+ FL and has shown sustained responses, with 57% of patients who achieved a CR still in remission at five years.1 Long-term data from the SC and IV arms of the GO29781 study will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
These data have been submitted to other healthcare authorities around the world, including the US Food and Drug Administration.
Phase III studies involving Lunsumio SC are ongoing, including the MorningLyte trial investigating Lunsumio SC in combination with lenalidomide in previously untreated FL. Lunsumio, along with Columvi® (glofitamab), is part of Roche’s industry-leading CD20xCD3 bispecific antibody portfolio. Continuing to explore new formulations and combinations of these medicines across different disease areas and lines of treatment is part of Roche’s commitment to improve the patient experience and provide more choice to suit diverse patient and healthcare system needs.
The GO29781 study is a phase II, multicentre, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of Lunsumio® (mosunetuzumab), administered both as an intravenous (IV) and subcutaneous (SC) treatment, in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The primary objective for the SC cohort was to show pharmacokinetic (PK) non-inferiority of the SC formulation of Lunsumio compared with the IV formulation, based on the study’s co-primary endpoints. Key secondary endpoints include complete response (CR) rate, objective response rate (ORR), duration of response, progression-free survival, safety and tolerability.
This approval is based on a primary analysis that explored Lunsumio administered subcutaneously in patients with 3L+ follicular lymphoma. Results from the primary analysis showed PK non-inferiority compared with IV administration, and the ORR and CR rates in patients treated with the fixed-duration, subcutaneous formulation of Lunsumio were 74.5% (95% confidence interval [CI]: 64.4-82.9%) and 58.5% (95% CI: 46.9-68.6%), respectively, as evaluated by the independent review faculty. The median duration of CR was 20.8 months (95% CI: 18.8-not evaluable [NE]) for patients receiving Lunsumio SC. The most common all-grade adverse events were injection-site reactions (60.6%; all Grade 1-2), fatigue (35.1%), and cytokine release syndrome (CRS; 29.8%). Overall, the rate and severity of CRS were low; events were low grade (Grade 1-2, 27.7%; Grade 3, 2.1%), occurred during cycle 1 and all fully resolved in a median of two days (range 1-15 days).3
Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases.2,5 It typically responds well to treatment but is often characterised by periods of remission and relapse.2 The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis.5 It is estimated that more than 110,000 people are diagnosed with FL each year worldwide.5,6
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development programme for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, other blood cancers and autoimmune disorders.
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell-engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3, and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
References
[1] Budde E, et al. Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study. Presented at: ASH Annual Meeting and Exposition; 2025 Dec 6-9; San Diego, CA, USA. Abstract #5352.
[2] Adult Non-Hodgkin Lymphoma Treatment-Health Professional Version (PDQ®) National Cancer Institute [Internet; cited November 2025]. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq#link/_552_toc.
[3] Roche data on file.
[4] Assouline S, et al. Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study. Presented at: ASH Annual Meeting and Exposition; 2025 Dec 6-9; San Diego, CA, USA. Abstract #5353.
[5] Cancer.Net. Lymphoma - Non-Hodgkin: Subtypes. [Internet; cited November 2025]. Available from: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes.
[6] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited November2025]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf.
The content above comes from the network. if any infringement, please contact us to modify.
临床结果上市批准ASH会议
2025-11-21
N Engl J Med[Jour] AND 393[volume] AND 1[issue]
新英格兰医学杂志 393卷1期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Defining Health Care “Corporatization”
美国医疗保健的企业化：界定医疗保健“企业化”
E.C. Fuse Brown
N Engl J Med; July 3, 2025; 393(1)：1-3
2
Self-Neglect in Older People — A Clinical, Social, and Ethical Dilemma
老年人自我忽视——临床、社会和伦理困境
K. Lees Haggerty and D.B. Reuben
N Engl J Med; July 3, 2025; 393(1)：4-6
3
Biologic Drugs and Medicare Price Negotiation
生物制剂与医保价格谈判
T.J. Hwang , N.L. Keating , and S.B. Dusetzina
N Engl J Med; July 3, 2025; 393(1)：6-9
4
The Autopsy Report
尸检报告
K. Klara
N Engl J Med; July 3, 2025; 393(1)：9-11
ORIGINAL ARTICLES（论著）
5
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
结肠癌辅助化疗后的结构化运动
K.S. Courneya and Others
N Engl J Med; July 3, 2025; 393(1)：13-25
6
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
与司美格鲁肽相比，替西帕肽治疗肥胖症的效果
L.J. Aronne and Others
N Engl J Med; July 3, 2025; 393(1)：26-36
7
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
局部晚期头颈癌的新型辅助和辅助帕博利珠单抗治疗
R. Uppaluri and Others
N Engl J Med; July 3, 2025; 393(1)：37-50
8
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥贝胆酸在心血管高危患者中的安全性和有效性
S.J. Nicholls and Others
N Engl J Med; July 3, 2025; 393(1)：51-61
REVIEW ARTICLE（综述）
9
Forensic Pathology
法医病理学
R.D. Folkerth , B.A. Sampson , and J.K. Graham
N Engl J Med; July 3, 2025; 393(1)：62-71
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
抗中性粒细胞胞浆抗体相关性血管炎导致的弥漫性肺泡出血
I.S. Lee
N Engl J Med; July 3, 2025; 393(1)：72
11
Frostbite Injury from Inhaled Nitrous Oxide Use
吸入一氧化二氮导致的冻伤损伤
M. Patrizio and M. Hayden
N Engl J Med; July 3, 2025; 393(1)：e1
CLINICAL PROBLEM-SOLVING（临床问题解决）
12
Caving In to Pressure
屈服于压力
S.I. Gomez-Villegas and Others
N Engl J Med; July 3, 2025; 393(1)：73-79
EDITORIALS（社论）
13
The Corporatization of U.S. Health Care — A New Perspective Series
美国医疗保健的企业化——一个新的观点与视角系列
D. Malina and Others
N Engl J Med; July 3, 2025; 393(1)：81-82
14
Extending Cancer Survival with Exercise — Time for Oncology to Act
通过运动延长癌症患者生存期——肿瘤学该行动了
M.L. Irwin
N Engl J Med; July 3, 2025; 393(1)：82-84
15
Semaglutide and Tirzepatide to Treat Obesity
司美格鲁肽和替西帕肽治疗肥胖症
F.L. Greenway
N Engl J Med; July 3, 2025; 393(1)：84-85
16
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer
在头颈癌根治性治疗中运用免疫疗法
A.J. Rosenberg and E.E. Vokes
N Engl J Med; July 3, 2025; 393(1)：85-87
SOUNDING BOARD（议事堂）
17
From the National Academy of Medicine: Climate Change and Human Health — A Research Agenda for Action
来自美国国家医学院的观点：气候变化与人类健康——行动研究议程
V.J. Dzau and Others
N Engl J Med; July 3, 2025; 393(1)：88-92
CORRESPONDENCE（读者来信）
18
Lifesaving Diagnosis through Prenatal Genomic Sequencing
通过产前基因组测序作出挽救生命的诊断
N Engl J Med; July 3, 2025; 393(1)：93-95
19
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
2型糖尿病患者强化血压控制
N Engl J Med; July 3, 2025; 393(1)：95-98
20
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
血流感染患者抗生素治疗7天与14天的对比
N Engl J Med; July 3, 2025; 393(1)：98-101
21
Dapagliflozin in Patients Undergoing TAVI
接受经导管主动脉瓣植入术患者使用达格列净的情况
N Engl J Med; July 3, 2025; 393(1)：101-103
22
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy
关于利司扑兰用于脊髓性肌萎缩症产前治疗的进一步评论
N Engl J Med; July 3, 2025; 393(1)：103-104
N Engl J Med[Jour] AND 393[volume] AND 2[issue]
新英格兰医学杂志 393卷2期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis
谁来关照美国？移民政策与即将到来的医疗劳动力危机
P.M.G. Santos , R. Jagsi , and C.I.A. Oronce
N Engl J Med; July 10, 2025; 393(2)：105-107
2
Exclusion of Elective Care from Hospital Financial Assistance Policies — Arresting a Troubling Development
医院财务援助政策中排除择期护理——遏制令人不安的发展态势
M.A. Hall and J. Garber
N Engl J Med; July 10, 2025; 393(2)：107-110
3
Libraries Burned, a Life Lived
图书馆被焚，人生如旅
T. Vijayan
N Engl J Med; July 10, 2025; 393(2)：110-111
ORIGINAL ARTICLES（论著）
4
As-Needed Albuterol–Budesonide in Mild Asthma
按需使用沙丁胺醇-布地奈德治疗轻度哮喘
C. LaForce and Others
N Engl J Med; July 10, 2025; 393(2)：113-124
5
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生风险的全球影响
The Global Cardiovascular Risk Consortium
N Engl J Med; July 10, 2025; 393(2)：125-138
6
Intravenous Tenecteplase before Thrombectomy in Stroke
卒中血栓切除术前静脉注射替奈普酶
Z. Qiu and Others
N Engl J Med; July 10, 2025; 393(2)：139-150
7
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
Inavolisib治疗PIK3CA突变型晚期乳腺癌的总生存期
K.L. Jhaveri and Others
N Engl J Med; July 10, 2025; 393(2)：151-161
REVIEW ARTICLE（综述）
8
Juvenile Idiopathic Arthritis
幼年特发性关节炎
C.I. Sandborg , G.S. Schulert , and Y. Kimura
N Engl J Med; July 10, 2025; 393(2)：162-174
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Whipple’s Disease with Endocarditis
伴有心内膜炎的惠普尔病
P. Ackermann and M.A. Borger
N Engl J Med; July 10, 2025; 393(2)：175
10
Incarcerated Femoral Hernia
嵌顿性股疝
P. Rana and H. Jivani
N Engl J Med; July 10, 2025; 393(2)：e2
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
11
Case 19-2025: A 69-Year-Old Man with Headache and Ataxia
病例19-2025：一名69岁男性，头痛且共济失调
A. Venkatesan and Others
N Engl J Med; July 10, 2025; 393(2)：176-184
EDITORIALS（社论）
12
Your Combination Asthma Inhaler — Don’t Leave Home without It!
你的联合哮喘吸入器——出门别忘了带！
J.M. Drazen
N Engl J Med; July 10, 2025; 393(2)：186-187
13
Estimates of Cardiovascular Risks and Benefits — When Knowing Is Not Enough
心血管风险和获益的评估——光知晓并不够
G.A. Mensah
N Engl J Med; July 10, 2025; 393(2)：187-189
14
Thrombolysis before Thrombectomy in Stroke — A Bridge Not Fallen
卒中血栓切除术前溶栓治疗——一座未坍塌的桥梁
T.W. Leung
N Engl J Med; July 10, 2025; 393(2)：189-191
SOUNDING BOARD（议事堂）
15
From the National Academy of Medicine: Transforming Health Care — Shared Commitments for a Learning Health System
来自美国国家医学院的观点：转变医疗保健模式——构建学习型医疗系统的共同承诺
J.L. Madara and Others
N Engl J Med; July 10, 2025; 393(2)：192-197
CORRESPONDENCE（通信）
16
Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024
2018-2024年美国携带tetM的淋病奈瑟菌的扩散情况
N Engl J Med; July 10, 2025; 393(2)：198-200
17
Atrial Appendage Closure after Ablation for Atrial Fibrillation
心房颤动消融术后左心耳封堵
N Engl J Med; July 10, 2025; 393(2)：200-203
18
Tumor-Infiltrating Clonal Hematopoiesis
肿瘤浸润性克隆性造血
N Engl J Med; July 10, 2025; 393(2)：203-205
19
Wealth and Mortality in the United States and Europe
美国和欧洲的财富与死亡率
N Engl J Med; July 10, 2025; 393(2)：205-207
20
Addressing Alcohol Use
应对酒精使用问题
N Engl J Med; July 10, 2025; 393(2)：207-208
N Engl J Med[Jour] AND 393[volume] AND 3[issue]
新英格兰医学杂志 393卷3期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Role of Public Health Agencies in Creating Vaccine Policy
公共卫生机构在制定疫苗政策中的作用
P. Marks
N Engl J Med; July 17, 2025; 393(3):209-211
2
New Mammography Tools — The Need for Clinically Meaningful Assessment Standards
新的乳腺钼靶工具——需要有临床意义的评估标准
B. Hyams , K. Kerlikowske , and R.F. Redberg
N Engl J Med; July 17, 2025; 393(3):211-213
3
The Second Life of Jacqui B.
Jacqui B.的第二人生。
M. Earnest and P. Khazanie
N Engl J Med; July 17, 2025; 393(3):214-215
ORIGINAL ARTICLES（论著）
4
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
杜伐鲁单抗在胃和胃食管结癌围手术期的应用
Y.Y. Janjigian and Others
N Engl J Med; July 17, 2025; 393(3):217-230
5
First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate
强的松或甲氨蝶呤治疗肺结节病的一线治疗
V. Kahlmann and Others
N Engl J Med; July 17, 2025; 393(3):231-242
6
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
环磷酰胺和环孢素预防移植物抗宿主病
D.J. Curtis and Others
N Engl J Med; July 17, 2025; 393(3):243-254
7
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis
小儿肠胃炎急诊后多剂量昂丹司琼的疗效
S.B. Freedman and Others
N Engl J Med; July 17, 2025; 393(3):255-266
8
Brief Report: Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death
简要报告：供体心脏在循环性死亡后快速恢复
A.M. Williams and Others
N Engl J Med; July 17, 2025; 393(3):267-274
9
Brief Report: On-Table Reanimation of a Pediatric Heart from Donation after Circulatory Death
简要报告：一名循环死亡后捐赠的儿童心脏在手术台上复活
J.A. Kucera , D.M. Overbey , and J.W. Turek
N Engl J Med; July 17, 2025; 393(3):275-280
REVIEW ARTICLE(综述)
10
The Spectrum of Fragile X Disorders
脆性X染色体紊乱谱系
R.J. Hagerman and P.J. Hagerman
N Engl J Med; July 17, 2025; 393(3):281-288
IMAGES IN CLINICAL MEDICINE（临床医学影像学）
11
Acrometastases
Acrometastases
H. O’Rourke and M. Iddawela
N Engl J Med; July 17, 2025; 393(3):289
12
Microcysts in Lithium-Induced Nephropathy
锂诱发肾病中的微囊
C.-H. Liao and K.-L. Liu
N Engl J Med; July 17, 2025; 393(3):e3
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马赛诸塞州总医院病例记录）
13
Case 20-2025: An 86-Year-Old Woman with Neck Swelling and Dysphagia
病例20-2025:86岁女性，颈部肿胀和吞咽困难
M.L. Russell and Others
N Engl J Med; July 17, 2025; 393(3):290-300
EDITORIALS（社论）
14
New Perioperative Strategy in Gastric Cancer
胃癌围手术期新策略
K. Shitara
N Engl J Med; July 17, 2025; 393(3):302-303
15
Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis?
甲氨蝶呤作为症状性肺结节病的初始治疗？
R.P. Baughman and E.E. Lower
N Engl J Med; July 17, 2025; 393(3):303-305
CORRESPONDENCE（通信）
16
Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss
单克隆抗血小板因子4抗体在复发性妊娠丢失中的作用
N Engl J Med; July 17, 2025; 393(3):306-309
17
Apixaban for Cancer-Associated Venous Thromboembolism
阿哌沙班治疗癌症相关静脉血栓栓塞
N Engl J Med; July 17, 2025; 393(3):309-312
N Engl J Med[Jour] AND 393[volume] AND 4[issue]
新英格兰医学杂志 393卷4期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Brain Death in Pregnancy — Abortion, Advance-Directive, or End-of-Life Law?
妊娠期脑死亡——人工流产、预先指示还是临终法律问题？
K. Watson
N Engl J Med; July 24, 2025; 393(4):313-315
2
The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors
最高法院未能保护跨性别未成年人的逻辑谬误
S. Skinner-Thompson
N Engl J Med; July 24, 2025; 393(4):316-318
3
The Promise of Real-World Data for Research — What Are We Missing?
现实世界数据研究的前景——我们错过了什么？
A.B. Abbasi , L.H. Curtis , and R.M. Califf
N Engl J Med; July 24, 2025; 393(4):318-321
4
Avocado and Salt
鳄梨和盐
G. Yi
N Engl J Med; July 24, 2025; 393(4):321-323
ORIGINAL ARTICLES(论著)
5
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
未接受胰岛素治疗的2型糖尿病患者的每周固定剂量艾塞那肽胰岛素
J. Rosenstock and Others
N Engl J Med; July 24, 2025; 393(4):325-335
6
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
德曲妥珠单抗或雷莫芦单抗联合紫杉醇治疗胃癌
K. Shitara and Others
N Engl J Med; July 24, 2025; 393(4):336-348
7
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
塔拉他单抗在小细胞肺癌铂基化疗后的疗效
G. Mountzios and Others
N Engl J Med; July 24, 2025; 393(4):349-361
8
Ivermectin to Control Malaria — A Cluster-Randomized Trial
伊维菌素控制疟疾-一项集群随机试验
C. Chaccour and Others
N Engl J Med; July 24, 2025; 393(4):362-375
REVIEW ARTICLE(综述)
9
Medical Education: Competency-Based Medical Education at the Front Lines of Patient Care
医学教育：位于患者护理第一线的基于能力的医学教育
D. Cooper and E.S. Holmboe
N Engl J Med; July 24, 2025; 393(4):376-388
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Löfgren’s Syndrome
洛夫格伦综合征
M. Hassan
N Engl J Med; July 24, 2025; 393(4):389
11
Hydroxychloroquine Retinal Toxicity
羟氯喹视网膜毒性
A. Donnelly and N. Horgan
N Engl J Med; July 24, 2025; 393(4):e4
INTERACTIVE MEDICAL CASE(互动式医疗案例)
12
A Case of Crackles
一例啰音病例
J.I. Hsu and Others
N Engl J Med; July 24, 2025; 393(4):e5
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 21-2025: A 75-Year-Old Man with Cough, Dyspnea, and Hypoxemia
病例21-2025:75岁男性，咳嗽、呼吸困难伴低氧血症
A.M. Anandaiah and Others
N Engl J Med; July 24, 2025; 393(4):390-399
EDITORIALS(社论)
14
Weekly Insulins and Therapeutic Burden in Type 2 Diabetes
每周胰岛素与2型糖尿病的治疗负担
J.R. Ingelfinger and C.J. Rosen
N Engl J Med; July 24, 2025; 393(4):401-402
15
Ivermectin against Malaria — Good News in Bad Times
伊维菌素抗疟疾——艰难时期的好消息
R.W. Steketee
N Engl J Med; July 24, 2025; 393(4):402-404
CLINICAL DECISIONS(临床决策)
16
Statin Therapy for Children
儿童他汀类药物治疗
H.K. Marwah, I.K. Luirink , and M. Mietus-Snyder
N Engl J Med; July 24, 2025; 393(4):405-407
CORRESPONDENCE(通信)
17
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
奥比妥珠单抗治疗活动性狼疮性肾炎的疗效和安全性
N Engl J Med; July 24, 2025; 393(4):408-410
18
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Lepodisiran -一种靶向脂蛋白(A)的长效干扰性小RNA
N Engl J Med; July 24, 2025; 393(4):411-412
19
BCG Revaccination to Prevent Tuberculosis
卡介苗复种预防结核病
N Engl J Med; July 24, 2025; 393(4):412-413
20
Evolving Epidemiology of Mpox in Africa in 2024
2024年非洲猴痘流行病学演变
N Engl J Med; July 24, 2025; 393(4):414
21
Enteral Nutrition in Hospitalized Adults
住院成人肠内营养
N Engl J Med; July 24, 2025; 393(4):415-416
N Engl J Med[Jour] AND 393[volume] AND 5[issue]
新英格兰医学杂志 393卷5期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat
Covid-19疫苗修订建议——美国疫苗接种政策受到威胁
J.L. Schwartz
N Engl J Med; July 31, 2025; 393(5):417-419
2
Public Policies, Social Narratives, and Population Health
公共政策、社会叙事与人口健康
A.S. Venkataramani , P.S. Tamber , and A. Iton
N Engl J Med; July 31, 2025; 393(5):419-421
3
Into the Valley of the Sick
进入病痛的之谷
S. Wesloh
N Engl J Med; July 31, 2025; 393(5):421-423
4
Interactive Perspective: Human Papillomavirus and Cancer
互动视角：人类乳头瘤病毒与癌症
J.R. Barzilay and Others
N Engl J Med; July 31, 2025; 393(5):e6
ORIGINAL ARTICLES(论著)
5
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
可测量的残留疾病–指导新诊断的骨髓瘤治疗
A. Perrot and Others
N Engl J Med; July 31, 2025; 393(5):425-437
6
Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease
线粒体捐献和植入前mtDNA疾病基因检测
L.A. Hyslop and Others
N Engl J Med; July 31, 2025; 393(5):438-449
7
A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery
心脏手术中急性等容血稀释的随机试验
F. Monaco and Others
N Engl J Med; July 31, 2025; 393(5):450-460
8
Brief Report: Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease
简要报告：线粒体捐赠在mtDNA疾病的生殖保健途径
R. McFarland and Others
N Engl J Med; July 31, 2025; 393(5):461-468
9
Brief Report: Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
简要报告：通过恢复t细胞受体信号传导来解决鳞状细胞癌
P. Ye and Others
N Engl J Med; July 31, 2025; 393(5):469-478
REVIEW ARTICLE(综述文章)
10
Motor Vehicle Crash Prevention
预防机动车辆碰撞
S.G. Klauer and Z.R. Doerzaph
N Engl J Med; July 31, 2025; 393(5):479-486
IMAGES IN CLINICAL MEDICINE(临床医学影像)
11
Spontaneous Intracranial Hypotension
自发性颅内低血压
S.B. Owais and Y. Kianirad
N Engl J Med; July 31, 2025; 393(5):487
12
Spiderweb-like Vessels in Retinopathy of Prematurity
早产儿视网膜病变中的蜘蛛网状血管
X. Zhao and G. Zhang
N Engl J Med; July 31, 2025; 393(5):e7
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 22-2025: A 19-Year-Old Woman with Seizurelike Activity and Odd Behaviors
案例22-2025：一名19岁女性出现癫痫样活动和怪异行为
J.A. Restrepo and Others
N Engl J Med; July 31, 2025; 393(5):488-496
EDITORIALS(社论)
14
Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma
开启新诊断多发性骨髓瘤个性化治疗的大门
P.G. Richardson , N.C. Munshi , and D.L. Longo
N Engl J Med; July 31, 2025; 393(5):498-500
15
Reducing the Risks of Mitochondrial Disease in Children
降低儿童线粒体疾病的风险
R. Lovell-Badge
N Engl J Med; July 31, 2025; 393(5):500-503
16
Science behind the Study: Advances in Preventing Transmission of Mitochondrial DNA Diseases
研究背后的科学：预防线粒体DNA疾病传播的进展
J. Steffann
N Engl J Med; July 31, 2025; 393(5):503-507
MEDICINE AND SOCIETY(医学与社会)
17
Reform and Remedy for Imprecision and Inequity — Ending the Race-Based Evaluation of Occupational Pulmonary Impairment
改革与修正——终结基于种族的职业性肺功能障碍评估
R. Khazanchi and Others
N Engl J Med; July 31, 2025; 393(5):508-514
CORRESPONDENCE(通信)
18
Phase 2a Study of Baxdrostat in Primary Aldosteronism
巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; July 31, 2025; 393(5):515-518
19
Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation
脉冲场或低温球囊消融治疗阵发性心房颤动
N Engl J Med; July 31, 2025; 393(5):518-520
N Engl J Med[Jour] AND 393[volume] AND 6[issue]
新英格兰医学杂志 393卷6期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
The Corporatization of U.S. Health Care: A Gilded Age for Patients? The Broken Promises of Profit-Driven Medicine
美国医疗保健公司化：病人的镀金时代？利润驱动的医药破碎的承诺
N. Tomes
N Engl J Med;August 7,2025;393(6):521-524
2
Lead Contamination in Milwaukee Schools — The Latest Episode in an Ongoing Toxic Pandemic
密尔沃基学校的铅污染——正在进行的毒性大流行的最新事件
M.S. Kanarek
N Engl J Med;August 7,2025;393(6):524-526
3
Training Health Communicators — The Need for a New Approach
培训健康传播者——需要一种新的方法
K. Panthagani and Others
N Engl J Med;August 7,2025;393(6):526-529
4
ER and Me
急诊室和我
E. Rourke
N Engl J Med;August 7,2025;393(6):529-531
ORIGINAL ARTICLES(论著)
5
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
芬尼酮联合恩格列净治疗慢性肾病和2型糖尿病
R. Agarwal and Others
N Engl J Med;August 7,2025;393(6):533-543
6
Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague
环丙沙星与氨基糖苷-环丙沙星治疗黑死病
R.V. Randremanana and Others
N Engl J Med;August 7,2025;393(6):544-555
7
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Vepdegestrant：一种用于晚期乳腺癌的PROTAC雌激素受体降解剂
M. Campone and Others
N Engl J Med;August 7,2025;393(6):556-568
8
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
一线用药卡米兹斯特兰治疗新发ESR1突变的晚期乳腺癌
F.-C. Bidard and Others
N Engl J Med;August 7,2025;393(6):569-580
REVIEW ARTICLE(综述)
9
Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism
中老年低促性腺激素性腺功能减退症患者的睾酮治疗
S. Bhasin and P.J. Snyder
N Engl J Med;August 7,2025;393(6):581-591
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
E-Cigarette– or Vaping-Associated Lung Injury
电子烟–或吸电子烟–相关肺损伤
M.Z. Roslly and S.A. Syed Rozhan
N Engl J Med;August 7,2025;393(6):592
11
Crusted Scabies
陈年的疥疮
Y.-J. Sun and H. Gong
N Engl J Med;August 7,2025;393(6):e8
CLINICAL PROBLEM-SOLVING(临床问题解决)
12
Gasping for Strength
喘息求生
D. Zarhin , H. Kolb , and A. Gadoth
N Engl J Med;August 7,2025;393(6):593-599
EDITORIALS(社论)
13
Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude
慢性肾病和2型糖尿病的联合治疗——充满希望的前奏
C. Zoccali and F. Mallamaci
N Engl J Med;August 7,2025;393(6):601-602
14
Chipping Away at an Old Foe
逐步击破旧敌
P. Mead
N Engl J Med;August 7,2025;393(6):603-604
15
Science behind the Study: Degradation of the Estrogen Receptor in Breast Cancer
研究背后的科学：乳腺癌中雌激素受体的降解
D.P. McDonnell
N Engl J Med;August 7,2025;393(6):604-608
MEDICINE AND SOCIETY(医学与社会)
16
Restoring the Infant Mortality Rate as a Measure of Societal Health and Well-Being
恢复将婴儿死亡率作为衡量社会健康和福祉的一项指标
E.A. Harrison , U. Ndulue , and B.O. Ojikutu
N Engl J Med;August 7,2025;393(6):609-614
CORRESPONDENCE(通信)
17
Xenon — Propelling Climbers to the Summits of the World’s Highest Mountains?
氙气—推动登山者登顶世界最高的山脉？
N Engl J Med;August 7,2025;393(6):615-616
18
Daratumumab for High-Risk Smoldering Multiple Myeloma
达雷妥尤单抗用于高危沉默型多发性骨髓瘤
N Engl J Med;August 7,2025;393(6):616-617
19
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
2型糖尿病患者自动胰岛素输送的随机试验
N Engl J Med;August 7,2025;393(6):617-619
20
Enhanced CAR T-Cell Therapy for Relapsed Lymphoma
增强型CAR T细胞疗法治疗复发性淋巴瘤
N Engl J Med;August 7,2025;393(6):619-620
21
Malaria
疟疾
N Engl J Med;August 7,2025;393(6):620-621
22
Neonatal Fc Receptor — Biology and Therapeutics
新生儿Fc受体——生物学与治疗
N Engl J Med;August 7,2025;393(6):621-623
NEngl J Med[Jour] AND 393[volume] AND 7[issue]
新英格兰医学杂志 393卷7期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Dismantling Public Health Infrastructure, Endangering American Lives
拆除公共卫生基础设施危及美国人的生命
T.R. Frieden
N Engl J Med;August 14,2025;393(7):625-627
2
Progress Lost — The Unraveling of Medicaid and the Affordable Care Act
停滞不前——医疗补助和《平价医疗法案》的瓦解
J. Oberlander
N Engl J Med;August 14,2025;393(7):628-629
3
The Resurgence of Private Law in American Health Care
美国医疗保健私法的复兴
C. Robertson and W.N. Epstein
N Engl J Med;August 14,2025;393(7):630-631
4
The Serendipitous Dance between Life and Death
生与死之间的偶然之舞
A. Zorigtbaatar
N Engl J Med;August 14,2025;393(7):632-633
ORIGINAL ARTICLES(论著)
5
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide和Semaglutide联合应用于超重或肥胖的成人
W.T. Garvey and Others
N Engl J Med;August 14,2025;393(7):635-647
6
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Cagrilintide–Semaglutide在超重或肥胖和2型糖尿病成人中的应用
M.J. Davies and Others
N Engl J Med;August 14,2025;393(7):648-659
7
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline
医院范围内的乳酸林格氏溶液与生理盐水的交叉试验
L. McIntyre and Others
N Engl J Med;August 14,2025;393(7):660-670
8
Risdiplam in Presymptomatic Spinal Muscular Atrophy
Risdiplam治疗亚临床脊髓性肌萎缩症
R.S. Finkel and Others
N Engl J Med;August 14,2025;393(7):671-682
REVIEW ARTICLE(综述)
9
Metabolic Dysfunction–Associated Steatotic Liver Disease
代谢功能障碍相关脂肪性肝病
G. Targher , L. Valenti , and C.D. Byrne
N Engl J Med;August 14,2025;393(7):683-698
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Snowman Sign in Pituitary Macroadenoma
垂体巨腺瘤的雪人征
Y. Zhou and W. Weng
N Engl J Med;August 14,2025;393(7):699
11
Ocular Gnathostomiasis
眼型囊尾蚴病
S. Karkhur and A. Gupta
N Engl J Med;August 14,2025;393(7):e9
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院病例记录)
12
Case 23-2025: A 28-Year-Old Woman with Respiratory Failure and Abnormal Chest Imaging
病例23-2025：一例28岁女性，呼吸衰竭伴胸部影像异常
W.J. Janssen and Others
N Engl J Med;August 14,2025;393(7):700-710
EDITORIALS(社论)
13
Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care
扩展肥胖和糖尿病的治疗目标工具箱
C.M. Hales
N Engl J Med;August 14,2025;393(7):712-714
14
Science behind the Study: Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug
研究背后的科学：小分子药物在遗传性疾病亚临床阶段中的治疗
C.J. Sumner
N Engl J Med;August 14,2025;393(7):714-717
15
Reviewers for the Journal, January–June 2025
本杂志2025年1月至6月的审稿人
E.J. Rubin
N Engl J Med;August 14,2025;393(7):718
CLINICAL DECISIONS(临床决策)
16
Managing Obesity
肥胖治疗
C.P. Kotanidis , A.M. Lincoff , and S.A. Shikora
N Engl J Med;August 14,2025;393(7)::719-721
CORRESPONDENCE(通信)
17
A Naturally Occurring Gain-of-Function Mutation in Factor VIII
因子VIII中自然发生的功能获得突变
N Engl J Med;August 14,2025;393(7):722-724
18
Oral Semaglutide and Cardiovascular Outcomes
口服司美格鲁肽与心血管预后
N Engl J Med;August 14,2025;393(7):724-725
19
Lorundrostat Efficacy and Safety in Uncontrolled Hypertension
Lorundrostat在未控制的高血压中的疗效和安全性
N Engl J Med;August 14,2025;393(7):725-727
20
Cancer of Unknown Primary Site
原发部位不明的癌症
N Engl J Med;August 14,2025;393(7):727-728
N Engl J Med[Jour] AND 393[volume] AND 8[issue]
新英格兰医学杂志 393卷 8期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Preventive Care at the Supreme Court
最高法院谈预防性医疗
N. Bagley
N Engl J Med; Aug 21/28, 2025; 393(8)：729-731
2
Regulating Private Equity in Health Care — The Massachusetts Model
医疗保健领域私募股权的监管——马萨诸塞模式
T.C. Tsai , G.S. Meyer , and D. Blumenthal
N Engl J Med; Aug 21/28, 2025; 393(8)：731-733
3
Reforming the Prescription Drug User Fee Program
改革处方药用户费用计划
T.J. Ziaks and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：734-736
4
The Consultant
顾问视角
T. Adzemovic
N Engl J Med; Aug 21/28, 2025; 393(8)：736-739
ORIGINAL ARTICLES（论著）
5
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
纳武利尤单抗联合化疗新辅助治疗肺癌的总生存期
P.M. Forde and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：741-752
6
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
艾琳扎奈坦特用于乳腺癌内分泌治疗引起的血管舒缩症状
F. Cardoso and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：753-763
7
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
吸入莫格拉斯汀治疗自身免疫性肺泡蛋白沉积症的3期试验
B.C. Trapnell and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：764-773
8
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
西米普利单抗辅助治疗对比安慰剂用于高危皮肤鳞状细胞癌
D. Rischin and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：774-785
REVIEW ARTICLE（综述）
9
Medical Education: Educational Strategies for Clinical Supervision of Artificial Intelligence Use
医学教育：人工智能应用临床监督的教育策略
R.-E.E. Abdulnour , B. Gin , and C.K. Boscardin
N Engl J Med; Aug 21/28, 2025; 393(8)：786-797
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Paraganglioma in the Organ of Zuckerkandl
颈动脉体旁器官副神经节瘤
R. Cohen and P. Hammill
N Engl J Med; Aug 21/28, 2025; 393(8)：798
11
Abdominojugular Reflux Test
腹颈静脉回流试验
S. Bent and G. Dhaliwal
N Engl J Med; Aug 21/28, 2025; 393(8)：e10
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 24-2025: A 32-Year-Old Woman with Fatigue and Myalgias
2025年第24例病例：一例32岁女性，疲劳伴肌痛
D.G. Kwolek and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：799-807
EDITORIALS（社论）
13
Redefining Lung Cancer Therapy — A Long-Awaited Shift in Strategy
重新定义肺癌治疗——期待已久的策略转变
V. Calvo
N Engl J Med; Aug 21/28, 2025; 393(8)：809-810
14
Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option
乳腺癌幸存者的更年期症状管理——一种有前景的新选择
A.H. Partridge
N Engl J Med; Aug 21/28, 2025; 393(8)：810-812
15
Science behind the Study: GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis
研究背后的科学：GM-CSF在自身免疫性肺泡蛋白沉积症中的作用
J.F. Seymour
N Engl J Med; Aug 21/28, 2025; 393(8)：812-816
SOUNDING BOARD（讨论专区）
16
The Path Forward for Vaccine Policy in the United States
美国疫苗政策的未来之路
H.Y. Chu and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：817-822
CORRESPONDENCE（读者来信）
17
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
抗BCMA CAR-T细胞治疗后CAR+ T细胞淋巴瘤的靶向治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：823-825
18
Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
司美格鲁肽治疗代谢相关脂肪性肝炎
N Engl J Med; Aug 21/28, 2025; 393(8)：826-828
19
Omitting Nodal Irradiation after Nodes Clear
淋巴结清除后省略淋巴结放疗
N Engl J Med; Aug 21/28, 2025; 393(8)：828-829
20
AAV Gene Therapy in Severe Hemophilia B
严重血友病B的腺相关病毒（AAV）基因治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：829-830
21
Screening for Prostate Cancer with a Polygenic Risk Score
基于多基因风险评分的前列腺癌筛查
N Engl J Med; Aug 21/28, 2025; 393(8)：831-832
CORRECTION（更正）
22
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
恩扎卢胺改善生化复发前列腺癌的预后
N Engl J Med; Aug 21/28, 2025; 393(8)：832
N Engl J Med[Jour] AND 393[volume] AND 9[issue]
新英格兰医学杂志 393卷 9期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: The Corporatization Deal — Health Care, Investors, and the Profit Priority
美国医疗保健的企业化：企业化交易——医疗保健、投资者与利润优先
A. Chandra and M. Shepard
N Engl J Med; Sep 4, 2025; 393(9)：833-835
2
Advancing Physician-Scientist Training in China — Challenges, Gaps, and Future Directions
推进中国医师科学家培养——挑战、差距与未来方向
P. Li and Others
N Engl J Med; Sep 4, 2025; 393(9)：836-838
3
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
中国药物创新的崛起——对美国及全球患者药物可及性的影响
K.N. Vokinger , G. Li , and O.J. Wouters
N Engl J Med; Sep 4, 2025; 393(9)：839-841
ORIGINAL ARTICLES（论著）
4
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
每月一次的马里德巴特卡弗拉鲁肽治疗肥胖——一项2期试验
A.M. Jastreboff and Others
N Engl J Med; Sep 4, 2025; 393(9)：843-857
5
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
干细胞衍生的完全分化胰岛用于治疗1型糖尿病
T.W. Reichman and Others
N Engl J Med; Sep 4, 2025; 393(9)：858-868
6
One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis
早期梅毒治疗中苄星青霉素G单次剂量与三次剂量的对比
E.W. Hook III and Others
N Engl J Med; Sep 4, 2025; 393(9)：869-878
7
Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia
单克隆抗体在肝素诱导的血小板减少症发病机制中的作用
J. Treverton and Others
N Engl J Med; Sep 4, 2025; 393(9)：879-886
8
Brief Report: Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression
简短报告：无需免疫抑制的移植同种异体β细胞存活情况
P.-O. Carlsson and Others
N Engl J Med; Sep 4, 2025; 393(9)：887-894
REVIEW ARTICLE（综述）
9
Management of Acute Type B Aortic Dissection
急性B型主动脉夹层的管理
F.F. Mussa and P. Kougias
N Engl J Med; Sep 4, 2025; 393(9)：895-905
VIDEOS IN CLINICAL MEDICINE（临床医学视频）
10
Ultrasound-Guided Paracentesis
超声引导下腹腔穿刺术
A. Kumar and Others
N Engl J Med; Sep 4, 2025; 393(9)：e11
IMAGES IN CLINICAL MEDICINE（临床医学图像）
11
Popeye Sign in Transthyretin Amyloidosis
转甲状腺素蛋白淀粉样变性中的“大力水手”征
S. Kurisu and H. Fujiwara
N Engl J Med; Sep 4, 2025; 393(9)：906
12
Radiation Pneumonitis
放射性肺炎
M. Peters and P. Jeene
N Engl J Med; Sep 4, 2025; 393(9)：e12
13
Hutchinson’s Sign in Subungual Melanoma In Situ
甲下原位黑色素瘤的Hutchinson征
M. Pasch and J. Tutein Nolthenius
N Engl J Med; Sep 4, 2025; 393(9)：e13
CLINICAL PROBLEM-SOLVING（疑难杂症求解探微）
14
A Fruitful Workup
卓有成效的检查过程
N. Jain and Others
N Engl J Med; Sep 4, 2025; 393(9)：907-914
EDITORIALS（社论）
15
A Tale of Two Diseases
两种疾病的故事
M.L. Collazo-Clavell
N Engl J Med; Sep 4, 2025; 393(9)：916-917
16
Science behind the Study: Replacement of Beta Cells for Type 1 Diabetes
研究背后的科学：1型糖尿病的β细胞替代
K.C. Herold and J.S. Pober
N Engl J Med; Sep 4, 2025; 393(9)：917-921
17
Antiquated Tools to Fight an Ancient Foe
用陈旧工具对抗古老敌人
L.A. Barbee and L.H. Bachmann
N Engl J Med; Sep 4, 2025; 393(9)：921-923
CORRESPONDENCE（通信）
18
Fulminant Viral Myocarditis Associated with Thogotovirus
与托高托病毒相关的暴发性病毒性心肌炎
N Engl J Med; Sep 4, 2025; 393(9)：924-926
19
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥比西特拉匹在高心血管风险患者中的安全性与有效性
N Engl J Med; Sep 4, 2025; 393(9)：926-928
20
Porcine Xenotransplantation in End-Stage Kidney Disease
终末期肾病中的猪异种移植
N Engl J Med; Sep 4, 2025; 393(9)：929-931
21
Malnutrition in Older Adults
老年人营养不良
N Engl J Med; Sep 4, 2025; 393(9)：931-933
22
Generative AI in Medicine
医学中的生成式人工智能
N Engl J Med; Sep 4, 2025; 393(9)：933-935
N Engl J Med[Jour] AND 393[volume] AND 10[issue]
新英格兰医学杂志 393卷10期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Efforts toward Equity: Caring for Patients with Intellectual or Developmental Disabilities —A Curriculum for Residents
迈向公平的努力：照顾有智力或发育障碍的患者——住院医师培训课程
L. Clarke and Others
N Engl J Med; Sep 11, 2025; 393(10)：937-939
2
Efforts toward Equity: Diaper Need —An Underrecognized Social Driver of Health
迈向公平的努力：尿布需求——一个未被充分认识的社会健康驱动因素
W. Berry , J. Bonville , and S.D. Blatt
N Engl J Med; Sep 11, 2025; 393(10)：939-940
3
Efforts toward Equity: Improving Care Coordination for Indigenous Patients with Cancer
迈向公平的努力：改善对患癌原住民患者的护理协调
A.E. Janitz and Others
N Engl J Med; Sep 11, 2025; 393(10)：940-942
4
Health and Medical Research Funding in a Divided America— How to Increase Support
分裂的美国在卫生与医学研究方面的资金投入——如何增加支持
R.J. Blendon , J.M. Benson , and N.B. Le
N Engl J Med; Sep 11, 2025; 393(10)：942-945
5
The End of Days
末日终结
I.Thomas
N Engl J Med; Sep 11, 2025; 393(10)：945-947
ORIGINAL ARTICLES（论著）
6
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Aficamten或美托洛尔单药治疗梗阻性肥厚型心肌病
P. Garcia-Pavia and Others
N Engl J Med; Sep 11, 2025; 393(10)：949-960
7
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Mavacamten治疗有症状的非梗阻性肥厚型心肌病
M.Y. Desai and Others
N Engl J Med; Sep 11, 2025; 393(10)：961-972
8
Multidomain Rehabilitation for Older Patients with Myocardial Infarction
针对老年心肌梗死患者的多领域康复治疗
E. Tonet and Others
N Engl J Med; Sep 11, 2025; 393(10)：973-982
9
Marburg Virus Disease in Rwanda, 2024 —Public Health and Clinical Responses
2024年卢旺达的马尔堡病毒病——公共卫生与临床应对措施
S. Nsanzimana and Others
N Engl J Med; Sep 11, 2025; 393(10)：983-993
SPECIAL ARTICLE（专题论著）
10
Medications for Opioid Use Disorder in County Jails —Outcomes after Release
县监狱中阿片类药物使用障碍的治疗药物——释放后的结果
P.D. Friedmann and Others
N Engl J Med; Sep 11, 2025; 393(10)：994-1003
REVIEW ARTICLE（综述）
11
Hypertrophic Cardiomyopathy
肥厚型心肌病
E. Braunwald
N Engl J Med; Sep 11, 2025; 393(10)：1004-1015
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Pityriasis Rosea
玫瑰糠疹
E.A. Rallis and C. Verros
N Engl J Med; Sep 11, 2025; 393(10)：1016
13
Acute Epididymo-orchitis in IgA Vasculitis
IgA血管炎伴急性附睾- 睾丸炎
S. Pariha and C. Hanna
N Engl J Med; Sep 11, 2025; 393(10)：e14
14
Ruptured Pulmonary Hydatid Cyst
肺包虫囊肿破裂
Y. Aydin and H. Ogul
N Engl J Med; Sep 11, 2025; 393(10)：e15
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
15
Case 25-2025: A 93-Year-Old Woman with Dyspnea and Fatigue
2025年第25例病例：一例93岁女性，呼吸困难伴疲劳
S.V. Arnold and Others
N Engl J Med; Sep 11, 2025; 393(10)：1017-1024
EDITORIAL（社论）
16
Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions
扩大肌球蛋白抑制在肥厚型心肌病中的作用——两种疾病的故事
A.V. Ambardekar
N Engl J Med; Sep 11, 2025; 393(10)：1026-1028
MEDICINE AND SOCIETY（医学与社会）
17
The Race-Correction Debates —Progress, Tensions, and Future Directions
种族校正争议——进展、紧张局势和未来方向
D.A. Vyas , L.G. Eisenstein , and D.S. Jones
N Engl J Med; Sep 11, 2025; 393(10)：1029-1036
CORRESPONDENCE（读者来信）
18
Long-Term Outcomes of the DanGer Shock Trial
DanGer休克试验的长期结果
N Engl J Med; Sep 11, 2025; 393(10)：1037-1038
19
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Efruxifermin治疗MASH所致的代偿性肝硬化
N Engl J Med; Sep 11, 2025; 393(10)：1038-1039
20
Once-Weekly Mazdutide in Obesity or Overweight
每周一次Mazdutide治疗肥胖或超重
N Engl J Med; Sep 11, 2025; 393(10)：1040
N Engl J Med[Jour] AND 393[volume] AND 11[issue]
新英格兰医学杂志 393卷11期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Reducing Tobacco Use Worldwide: Integrating Pharmacotherapy into Tobacco Control in Low- and Middle-Income Countries — A Critical Need
全球范围内减少烟草使用：将药物治疗纳入中低收入国家烟草控制——一项迫切需求
N.A. Rigotti , N. Walker , and A.S. Amer Nordin
N Engl J Med; Sep 18, 2025; 393(11)：1041-1044
2
Protecting Medicaid Enrollees with Chronic Conditions amid Work Requirements
在工作要求下保护患有慢性病的医疗补助计划（Medicaid）参保人
J.Z. Ayanian
N Engl J Med; Sep 18, 2025; 393(11)：1044-1046
3
Ultraprocessed Food on an Ultrafast Track
超加工食品驶入超速发展轨道
D.S. Ludwig
N Engl J Med; Sep 18, 2025; 393(11)：1046-1049
4
The Consequences of Silencing the “Voice of CDC”
“美国疾控中心之声”被消音的后果
S.A. Rasmussen and Others
N Engl J Med; Sep 18, 2025; 393(11)：e16
5
Medicaid on the Chopping Block
医疗补助计划（Medicaid）面临削减
E. Park
N Engl J Med; Sep 18, 2025; 393(11)：e17
ORIGINAL ARTICLES（论著）
6
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
低剂量阿司匹林用于PI3K突变的局限性结直肠癌
A. Martling and Others
N Engl J Med; Sep 18, 2025; 393(11)：1051-1064
7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Orforglipron（一种口服小分子GLP-1受体激动剂）用于早期2型糖尿病
J. Rosenstock and Others
N Engl J Med; Sep 18, 2025; 393(11)：1065-1076
8
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
口服司美格鲁肽25 mg用于超重或肥胖成人
S. Wharton and Others
N Engl J Med; Sep 18, 2025; 393(11)：1077-1087
9
Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation
比例辅助通气以缩短机械通气时间
K.J. Bosma and Others
N Engl J Med; Sep 18, 2025; 393(11)：1088-1103
REVIEW ARTICLE（综述）
10
Tumor Lysis Syndrome
肿瘤溶解综合征
R.G. Bociek and M. Lunning
N Engl J Med; Sep 18, 2025; 393(11)：1104-1116
IMAGES IN CLINICAL MEDICINE（临床医学影像）
11
Subcutaneous Panniculitis-like T-Cell Lymphoma
皮下脂膜炎样T细胞淋巴瘤
S. Okada and M. Nishikubo
N Engl J Med; Sep 18, 2025; 393(11)：1117
12
Primary Varicella Infection
原发性水痘感染
O. van Not and D. Rauwerdink
N Engl J Med; Sep 18, 2025; 393(11)：e18
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
13
Case 26-2025: An 11-Year-Old Girl with Chest Pain and Bone and Liver Lesions
2025年第26例病例：一例11岁女孩，胸痛伴骨和肝脏病变
L.P. Carter and Others
N Engl J Med; Sep 18, 2025; 393(11)：1118-1127
EDITORIALS（社论）
14
Reducing Tobacco Use Worldwide — A New Perspective Series
全球减少烟草使用——新观点系列
N.A. Rigotti and Others
N Engl J Med; Sep 18, 2025; 393(11)：1129-1130
15
An Aspirin a Day for Improved Colorectal Cancer Outcomes
每日一片阿司匹林以改善结直肠癌预后
R.M. Goldberg and J.A. Meyerhardt
N Engl J Med; Sep 18, 2025; 393(11)：1131-1132
16
Mimicking Complex Receptor Actions with Small(ish) Molecules
用小（型）分子模拟复杂受体作用
D.B. Lowe
N Engl J Med; Sep 18, 2025; 393(11)：1133-1134
CORRESPONDENCE（通信）
17
Introduction of Mpox Virus Clade Ib into the Republic of the Congo
猴痘病毒Ib分支传入刚果共和国
N Engl J Med; Sep 18, 2025; 393(11)：1135-1137
18
Perioperative Pembrolizumab in Head and Neck Cancer
围手术期帕博利珠单抗用于头颈癌
N Engl J Med; Sep 18, 2025; 393(11)：1138-1139
19
Ondansetron after ED Visits in Children with Gastroenteritis
儿童胃肠炎急诊就诊后使用昂丹司琼
N Engl J Med; Sep 18, 2025; 393(11)：1139-1141
20
Navigating the Discontinuity Crisis in Medical Education
应对医学教育中的断层危机
N Engl J Med; Sep 18, 2025; 393(11)：1141-1143
21
Fetal Hereditary Thrombotic Thrombocytopenic Purpura
胎儿遗传性血栓性血小板减少性紫癜
N Engl J Med; Sep 18, 2025; 393(11)：1143-1144
N Engl J Med[Jour] AND 393[volume] AND 12[issue]
新英格兰医学杂志 393卷12期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Structural and Scientific Racism, Science, and Health — Evidence versus Ideology
结构性与科学层面的种族主义、科学与健康——证据与意识形态之争
N. Krieger and M.T. Bassett
N Engl J Med; Sep 25, 2025; 393(12)：1145-1148
2
From Health to Wealth — Reframing Global Aid through the Gates Foundation’s Final Chapter
从健康到财富——通过盖茨基金会的终章重新构建全球援助框架
S. Phillips
N Engl J Med; Sep 25, 2025; 393(12)：1148-1151
3
Dr. Kolhouse and the Cowboy
科尔豪斯博士与牛仔
M. Earnest
N Engl J Med; Sep 25, 2025; 393(12)：1151-1153
ORIGINAL ARTICLES（论著）
4
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
地高辛用于射血分数降低的心力衰竭患者
U. Bavendiek and Others
N Engl J Med; Sep 25, 2025; 393(12)：1155-1165
5
Apixaban for Extended Treatment of Provoked Venous Thromboembolism
阿哌沙班用于诱因性静脉血栓栓塞症的延长治疗
G. Piazza and Others
N Engl J Med; Sep 25, 2025; 393(12)：1166-1176
6
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
基于可测量残留病灶指导的慢性淋巴细胞白血病治疗
T. Munir and Others
N Engl J Med; Sep 25, 2025; 393(12)：1177-1190
7
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
卒中静脉溶栓后早期输注替罗非班
C. Tao and Others
N Engl J Med; Sep 25, 2025; 393(12)：1191-1201
REVIEW ARTICLE（综述）
8
Medical Education: Advancing Diagnostic Excellence through Medical Education in Diagnostic Equity
医学教育：通过诊断公平性医学教育推进诊断卓越
D.M. Connor , M.L. Lypson , and C.M. Gonzalez
N Engl J Med; Sep 25, 2025; 393(12)：1202-1214
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Systemic Mastocytosis
系统性肥大细胞增多症
L. Neves da Silva and A.M. Monteiro
N Engl J Med; Sep 25, 2025; 393(12)：1215
10
Doxycycline-Induced Phototoxicity
多西环素诱导的光毒性反应
G. Boyd and C. Cheng
N Engl J Med; Sep 25, 2025; 393(12)：e19
INTERACTIVE MEDICAL CASE（互动式医学病例）
11
A Fizzy Fix
气泡疗法
M.A. Crane and Others
N Engl J Med; Sep 25, 2025; 393(12)：e20
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 27-2025: A 53-Year-Old Man with Embolic Stroke and Left Ventricular Apical Aneurysm
2025年第27例病例：一例53岁男性，患有栓塞性卒中及左心室心尖部动脉瘤
G.C. Stewart and Others
N Engl J Med; Sep 25, 2025; 393(12)：1216-1225
EDITORIALS（社论）
13
Digitoxin — A Reminder for Digoxin
地高辛——对洋地黄的提醒
M.A. Pfeffer
N Engl J Med; Sep 25, 2025; 393(12)：1227-1228
14
Art within Evidence — Balancing Anticoagulant Duration in VTE Care
证据中的艺术——平衡静脉血栓栓塞症护理中的抗凝时长
N.A. Zakai
N Engl J Med; Sep 25, 2025; 393(12)：1229-1230
CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义）
15
Transformative Research in Cystic Fibrosis
囊性纤维化的变革性研究
E.J. Sorscher
N Engl J Med; Sep 25, 2025; 393(12)：1231-1234
16
Surprisingly Complex Assemblies from Low-Complexity Domains
来自低复杂度结构域的惊人复杂组装
T. Mittag
N Engl J Med; Sep 25, 2025; 393(12)：1235-1238
CORRESPONDENCE（通信）
17
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
CD19嵌合抗原受体T细胞疗法治疗多重耐药性溃疡性结肠炎
N Engl J Med; Sep 25, 2025; 393(12)：1239-1241
18
Nonoperative Management of Mismatch Repair–Deficient Tumors
错配修复缺陷肿瘤的非手术治疗
N Engl J Med; Sep 25, 2025; 393(12)：1241-1243
19
Cerebral Embolic Protection during TAVI
经导管主动脉瓣置换术中的脑栓塞保护
N Engl J Med; Sep 25, 2025; 393(12)：1243-1245
20
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生估计的全球影响
N Engl J Med; Sep 25, 2025; 393(12)：1245-1248
N Engl J Med[Jour] AND 393[volume] AND 13[issue]
新英格兰医学杂志 393卷13期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Insight into Corporate Governance — What Motivates Hospitals and Delivery Systems
美国医疗保健的企业化：企业治理洞察——医院和医疗交付系统的动机何在
S. Lipstein
N Engl J Med; Oct 2, 2025; 393(13)：1249-1251
2
The Risks of Pharmaceutical Tariffs for Generic Drug Availability
药品关税对仿制药供应的风险
T.J. Hwang , Q.-D. Trinh , and K.N. Vokinger
N Engl J Med; Oct 2, 2025; 393(13)：1252-1253
3
Goals for Opioid Use Disorder Medications — Protection, Remission, and Recovery
阿片类药物使用障碍治疗药物的目标——保护、缓解和康复
A.T. McLellan and N.D. Volkow
N Engl J Med; Oct 2, 2025; 393(13)：1253-1255
ORIGINAL ARTICLES（论著）
4
Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis
伴有胃肠炎的严重急性营养不良的静脉补液治疗
K. Maitland and Others
N Engl J Med; Oct 2, 2025; 393(13)：1257-1268
5
Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk
医学影像与儿童和青少年血液系统癌症风险
R. Smith-Bindman and Others
N Engl J Med; Oct 2, 2025; 393(13)：1269-1278
6
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
使用针对APOC3的奥列扎森治疗中度高甘油三酯血症
B.A. Bergmark and Others
N Engl J Med; Oct 2, 2025; 393(13)：1279-1291
7
Clesrovimab for Prevention of RSV Disease in Healthy Infants
克莱斯罗维玛布预防健康婴儿呼吸道合胞病毒疾病
H.J. Zar and Others
N Engl J Med; Oct 2, 2025; 393(13)：1292-1303
8
Home-Based Care for Hypertension in Rural South Africa
南非农村地区高血压的家庭护理
M.J. Siedner and Others
N Engl J Med; Oct 2, 2025; 393(13)：1304-1314
REVIEW ARTICLE（综述）
9
Monoclonal Gammopathy of Undetermined Significance
意义未定的单克隆丙种球蛋白病
S.V. Rajkumar and S. Kumar
N Engl J Med; Oct 2, 2025; 393(13)：1315-1326
IMAGES IN CLINICAL MEDICINE（临床医学图像）
10
Uremic Frost
尿毒症霜
M.A. Wani and Z.H. Shah
N Engl J Med; Oct 2, 2025; 393(13)：1327
11
Herpes Simplex Virus Esophagitis
单纯疱疹病毒食管炎
A.Agarwal and A. Agarwal
N Engl J Med; Oct 2, 2025; 393(13)：e21
CLINICAL PROBLEM-SOLVING（疑难杂症破解之道）
12
A Shifting Frame
视角转换
A.Terrett and Others
N Engl J Med; Oct 2, 2025; 393(13)：1328-1334
EDITORIALS（社论）
13
Data versus Dogma — Safety of Intravenous Rehydration in Severely Malnourished Children
数据与教条之争——严重营养不良儿童静脉补液的安全性
M.J. Peters
N Engl J Med; Oct 2, 2025; 393(13)：1336-1337
14
Studying Cancer Risks Associated with Diagnostic Procedures — Interpret Wisely
研究诊断程序相关的癌症风险——明智解读
L.M. Morton
N Engl J Med; Oct 2, 2025; 393(13)：1337-1339
CLINICAL DECISIONS（临床决策）
15
Allergy or Assumption of Allergy — When to Test for a Penicillin Allergy
过敏还是假定的过敏——何时进行青霉素过敏测试
H. Marwah , A. Ramsey , and E.M. Macy
N Engl J Med; Oct 2, 2025; 393(13)：1340-1342
CORRESPONDENCE（读者来信）
16
Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease
克莱斯罗维玛布用于有严重呼吸道合胞病毒疾病高风险的婴儿和儿童
N Engl J Med; Oct 2, 2025; 393(13)：1343-1345
17
Nerandomilast in Patients with Pulmonary Fibrosis
奈拉度米拉司特用于肺纤维化患者
N Engl J Med; Oct 2, 2025; 393(13)：1346-1347
18
Trastuzumab Deruxtecan in Gastric Cancer
德曲妥珠单抗用于胃癌
N Engl J Med; Oct 2, 2025; 393(13)：1347-1348
19
Tarlatamab in Small-Cell Lung Cancer
塔拉他玛布用于小细胞肺癌
N Engl J Med; Oct 2, 2025; 393(13)：1348-1349
20
Cyclophosphamide and Cyclosporin for GVHD Prevention
环磷酰胺和环孢素预防移植物抗宿主病
N Engl J Med; Oct 2, 2025; 393(13)：1349-1351
N Engl J Med[Jour] AND 393[volume] AND 14[issue]
新英格兰医学杂志 393卷14期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Occupational Health and Safety on the Chopping Block — What’s at Stake?
职业健康与安全岌岌可危——有何利害关系？
A.T. Gabrielson and C. Corwin
N Engl J Med; Oct 9, 2025; 393(14)：1353-1355
2
Emergency Medicaid at Risk — Preserving State Authority and Access to Care
紧急医疗补助岌岌可危——维护州政府权限与医疗保障可及性
J.A. Budhu and Others
N Engl J Med; Oct 9, 2025; 393(14)：1356-1358
3
Pharmaceutical Wholesalers — Under-the-Radar Middlemen?
药品批发商——鲜为人知的中间商？
H. Rooke-Ley and R.E. Sachs
N Engl J Med; Oct 9, 2025; 393(14)：1358-1360
4
“You Still Going to Be Doing This?”
“你还会坚持下去吗？”
E.J. Shapiro
N Engl J Med; Oct 9, 2025; 393(14)：1360-1361
ORIGINAL ARTICLES（论著）
5
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
巴克斯德罗沙特（Baxdrostat）治疗未控制及难治性高血压的疗效与安全性
J.M. Flack and Others
N Engl J Med; Oct 9, 2025; 393(14)：1363-1374
6
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
针对伴有多发性神经病的遗传性转甲状腺素蛋白淀粉样变性病的Nexiguran Ziclumeran基因编辑疗法
J.D. Gillmore and Others
N Engl J Med; Oct 9, 2025; 393(14)：1375-1386
7
Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases
靶向室内喷洒预防埃及伊蚊传播疾病的随机试验
N.E. Dean and Others
N Engl J Med; Oct 9, 2025; 393(14)：1387-1398
8
Permethrin-Treated Baby Wraps for the Prevention of Malaria
使用氯菊酯处理过的婴儿包裹物预防疟疾
R.M. Boyce and Others
N Engl J Med; Oct 9, 2025; 393(14)：1399-1408
REVIEW ARTICLE（综述）
9
Idiopathic Intracranial Hypertension
特发性颅内压增高
J.C. Horton
N Engl J Med; Oct 9, 2025; 393(14)：1409-1419
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Butterfly Vertebra
蝴蝶椎
S. Ding and X. Pan
N Engl J Med; Oct 9, 2025; 393(14)：1420
11
Oral Verruciform Xanthomas
口腔疣状黄瘤
G. Anaya-Saavedra and M. Vázquez-Garduño
N Engl J Med; Oct 9, 2025; 393(14)：e22
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 28-2025: A 36-Year-Old Man with Abdominal Pain, Fever, and Hypoxemia
2025年第28例病例：一例36岁男性，出现腹痛、发热伴低氧血症
G. Dhaliwal and Others
N Engl J Med; Oct 9, 2025; 393(14)：1421-1434
EDITORIAL（社论）
13
Aldosterone Synthase Inhibition for Hypertension
醛固酮合成酶抑制剂治疗高血压
T.J. Guzik and M. Tomaszewski
N Engl J Med; Oct 9, 2025; 393(14)：1436-1439
CORRESPONDENCE（读者来信）
14
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
Exagamglogene Autotemcel中CRISPR-Cas9编码的特异性——更新
N Engl J Med; Oct 9, 2025; 393(14)：1440-1442
15
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes
每周固定剂量艾氟司他（Efsitora）胰岛素治疗2型糖尿病
N Engl J Med; Oct 9, 2025; 393(14)：1442-1444
16
Diphtheria Outbreak among Migrants in Europe
欧洲移民群体中的白喉疫情
N Engl J Med; Oct 9, 2025; 393(14)：1444-1445
17
Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
通过恢复T细胞受体信号传导清除鳞状细胞癌
N Engl J Med; Oct 9, 2025; 393(14)：1446-1447
18
Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation
2025年第17例病例：一例肾移植后出现呼吸衰竭和休克的患者
N Engl J Med; Oct 9, 2025; 393(14)：1447-1448
N Engl J Med[Jour] AND 393[volume] AND 15[issue]
新英格兰医学杂志 393卷15期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Reducing Tobacco Use Worldwide: The Contribution of Digital Treatment to Efforts to Reduce Global Tobacco Use
减少全球烟草使用:数字治疗对减少全球烟草使用的贡献
F. Naughton and A. Nadkarni
N Engl J Med; October16, 2025; 393(15):1449-1452
2
Advancing Surveillance of Health Care–Associated Infections — Targeting Hospital-Onset Sepsis
推进卫生保健相关感染的监测-针对医院发生的败血症
F. Manzoor , C. Rhee , and M. Klompas
N Engl J Med; October16, 2025; 393(15):1452-1454
3
The AI Frontier in Humanitarian Aid — Embracing Possibilities and Addressing Risks
人工智能在人道主义援助中的前沿——拥抱可能性与应对风险
M. Barry , J. Hansen , and G.L. Darmstadt
N Engl J Med; October16, 2025; 393(15):1454-1457
4
Proliferation of Prior Authorization in Traditional Medicare — None the WISeR?
传统医疗中预先授权的扩散——更明智了吗？
M. Liu , K.T. Kadakia , and R.K. Wadhera
N Engl J Med; October16, 2025; 393(15):1457-1459
5
On Bearing Witness
关于见证
S. Attar
N Engl J Med; October16, 2025; 393(15):1459-1461
6
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Alive and Kicking — NOS Episode 3.1
未作特别说明（NOS）——第三季：初级医疗的永恒危机：愈演愈烈 ——NOS第3季第1集
N Engl J Med; October16, 2025; 393(15):e24
ORIGINAL ARTICLES(论著)
7
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
宫颈癌中仅行前哨淋巴结活检或联合淋巴结清扫术
H. Tu and Others
N Engl J Med; October16, 2025; 393(15):1463-1474
8
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
Telitacicept治疗系统性红斑狼疮的3期临床试验
R.F. van Vollenhoven and Others
N Engl J Med; October16, 2025; 393(15):1475-1485
9
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
基因治疗腺苷脱氨酶缺乏症的长期安全性和有效性
C. Booth and Others
N Engl J Med; October16, 2025; 393(15):1486-1497
10
Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality
马里婴儿大量使用阿奇霉素以降低死亡率
F.C. Haidara and Others
N Engl J Med; October16, 2025; 393(15):1498-1508
CLINICAL PRACTICE(临床实践)
11
Hair Loss in Women
女性脱发
E.A. Olsen
N Engl J Med; October16, 2025; 393(15):1509-1520
IMAGES IN CLINICAL MEDICINE(临床医学影像)
12
Pneumococcal Sepsis in a Patient with Asplenia and Hypogammaglobulinemia
脾缺失合并低丙种球蛋白血症患者发生肺炎球菌性败血症
S.J. Starke and I. Miller
N Engl J Med; October16, 2025; 393(15):1521
13
Stercoral Colitis
粪石性结肠炎
A. Bajer and E. Levine
N Engl J Med; October16, 2025; 393(15): e23
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院的病例记录)
14
Case 29-2025: A 43-Year-Old Woman with Depression, Suicidal Ideation, and Fever
病例29-2025：一例43岁女性，抑郁、自杀倾向伴发热
M.S. Abers and Others
N Engl J Med; October16, 2025; 393(15):1522-1531
EDITORIALS(社论)
15
Risk and Benefit
风险与收益
E.J. Rubin
N Engl J Med; October16, 2025; 393(15):1533-1534
16
Sentinel Lymphadenectomy for Early-Stage Cervical Cancer — the New Standard?
早期宫颈癌的前哨淋巴结切除术——新标准？
K. Bixel
N Engl J Med; October16, 2025; 393(15):1534-1536
MEDICINE AND SOCIETY(医学与社会)
17
The Primary Care Puzzle: Is a Long-Simmering Crisis Boiling Over? U.S. Primary Care Today
初级医疗之谜：长期酝酿的危机正在爆发？美国初级医疗现状
L. Rosenbaum
N Engl J Med; October16, 2025; 393(15):1537-1541
CORRESPONDENCE(通信)
18
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
体内CD19 CAR T细胞疗法治疗难治性系统性红斑狼疮
N Engl J Med; October16, 2025; 393(15):1542-1544
19
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
顽固性自身免疫性疾病患者的BCMA T细胞接合疗法
N Engl J Med; October16, 2025; 393(15):1544-1547
20
Competency-Based Medical Education at the Front Lines of Patient Care
以能力为本的一线患者护理医学教育
N Engl J Med; October16, 2025; 393(15):1548-1550
21
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism
更多关于巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; October16, 2025; 393(15):1550-1552
N Engl J Med[Jour] AND 393[volume] AND 16[issue]
新英格兰医学杂志 393卷16期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Involving Palliative Care to Improve Outcomes in Sickle Cell Disease
纳入姑息治疗以改善镰状细胞病预后
E. Nwogu-Onyemkpa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1553-1556
2
Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps
羟基脲治疗镰状细胞贫血三十年——科学进展与全球健康差距
E. Costa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1556-1559
3
Fetal Personhood and Reproductive Criminalization — Implications for Patients, Clinicians, and Public Health
胎儿人格与生殖犯罪化——对患者、临床医生和公共卫生的影响
T. Riley and A. Hassan
N Engl J Med; Oct 23, 2025; 393(16)：1559-1561
4
Living in the Present Tense
活在当下
J.A. Feinstein
N Engl J Med; Oct 23, 2025; 393(16)：1561-1563
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Can AI Solve Primary Care? — NOS Episode 3.2
未作他类说明——第三季：初级保健的永恒危机：人工智能能否解决初级保健问题？——未作他类说明第3.2集
N Engl J Med; Oct 23, 2025; 393(16)：e25
ORIGINAL ARTICLES（论著）
6
Hypertonic Saline or Carbocisteine in Bronchiectasis
高渗盐水或羧甲司坦治疗支气管扩张症
J.M. Bradley and Others
N Engl J Med; Oct 23, 2025; 393(16)：1565-1577
7
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
接受口服抗凝治疗的慢性冠状动脉综合征患者使用阿司匹林的情况
G. Lemesle and Others
N Engl J Med; Oct 23, 2025; 393(16)：1578-1588
8
Common Diseases in Clinical Cohorts — Not Always What They Seem
临床队列中的常见疾病——并不总是如表面所见
F. Rahimov and Others
N Engl J Med; Oct 23, 2025; 393(16)：1589-1598
9
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
诊断后第一年内使用索塔生塞普（Sotatercept）治疗肺动脉高压
V.V. McLaughlin and Others
N Engl J Med; Oct 23, 2025; 393(16)：1599-1611
10
Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
2024-2025年新冠疫苗与美国退伍军人新冠结局的关联
M. Cai , Y. Xie , and Z. Al-Aly
N Engl J Med; Oct 23, 2025; 393(16)：1612-1623
REVIEW ARTICLE（综述）
11
Medical Education: Educational Strategies to Prepare Trainees for Clinical Uncertainty
医学教育：为受训者应对临床不确定性做准备的教育策略
J.S. Ilgen and G. Dhaliwal
N Engl J Med; Oct 23, 2025; 393(16)：1624-1632
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Human East African Trypanosomiasis
人类东非锥虫病
L. Veletzky and S. Winkler
N Engl J Med; Oct 23, 2025; 393(16)：1633
13
Thoracic Ectopia Cordis
胸部心脏异位
Z. Duric and H. Gasparovic
N Engl J Med; Oct 23, 2025; 393(16)：e26
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 30-2025: An 82-Year-Old Woman with Abdominal Distention, Edema, and Pleural Effusion
2025年30号病例：一名82岁女性，出现腹部膨隆、水肿和胸腔积液
Z. Kanjee and Others
N Engl J Med; Oct 23, 2025; 393(16)：1634-1644
EDITORIALS（社论）
15
Time to Reconsider Mucoactive Agents for Airway Clearance
是时候重新考虑用于气道廓清的黏液活性药物了
J. Hansen-Flaschen and G. Tino
N Engl J Med; Oct 23, 2025; 393(16)：1646-1647
16
A Rare-in-Common Paradigm for Precision Genomic Medicine
精准基因组医学中的“罕见共性”范式
P.N. Robinson
N Engl J Med; Oct 23, 2025; 393(16)：1648-1649
CORRESPONDENCE（读者来信）
17
Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia
柬埔寨人畜共患高致病性禽流感A(H5N1)病毒卷土重来
N Engl J Med; Oct 23, 2025; 393(16)：1650-1652
18
Perioperative Durvalumab in Gastric Cancer
胃癌围手术期使用度伐利尤单抗
N Engl J Med; Oct 23, 2025; 393(16)：1652-1654
19
Tirzepatide vs. Semaglutide for Obesity Treatment
替西帕肽与司美格鲁肽治疗肥胖症的对比
N Engl J Med; Oct 23, 2025; 393(16)：1654-1656
N Engl J Med[Jour] AND 393[volume] AND 17[issue]
新英格兰医学杂志 393卷17期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Efforts toward Equity: Disparities in Kidney Disease and the Race-Neutral eGFR — Research and Action in NYC’s Public Hospital System
努力迈向公平：肾脏疾病中的差异与无种族差异的估算肾小球滤过率（eGFR）——纽约市公立医院系统的研究与行动
A. Bocour and Others
N Engl J Med; Oct 30, 2025; 393(17)：1657-1658
2
Efforts toward Equity: Automating WIC Screening and Enrollment in Pediatric Primary Care
努力迈向公平：儿科初级保健中妇女、婴儿和儿童（WIC）筛查与登记的自动化
L. Suarez and Others
N Engl J Med; Oct 30, 2025; 393(17)1659-1660
3
Efforts toward Equity: Listening and Responding to Community Voices — The Community Wellness HUB
努力迈向公平：倾听并回应社区声音——社区健康中心
L.S. Jemmott and Others
N Engl J Med; Oct 30, 2025; 393(17)：1660-1662
4
Flaws in the FDA’s New Priority Voucher Program
美国食品药品监督管理局（FDA）新优先审评券计划的缺陷
D. Carpenter , T.J. Hwang , and A.S. Kesselheim
N Engl J Med; Oct 30, 2025; 393(17)：1662-1664
5
Standing by Our Colleagues in Gaza — A Plea to the U.S. Medical Community
声援我们在加沙的同行——对美国医学界的呼吁
F. Sidhwa and Others
N Engl J Med; Oct 30, 2025; 393(17)：1664-1667
6
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Misunderstandings — NOS Episode 3.3
未明确说明——第三季：初级保健的长期危机：误解——未明确说明（NOS）第3.3集
N Engl J Med; Oct 30, 2025; 393(17)：e27
ORIGINAL ARTICLES（论著）
7
European Study of Prostate Cancer Screening — 23-Year Follow-up
欧洲前列腺癌筛查研究——23年随访结果
M.J. Roobol and Others
N Engl J Med; Oct 30, 2025; 393(17)：1669-1680
8
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
阿米万他单抗联合拉泽替尼治疗EGFR突变型晚期非小细胞肺癌的总生存期
J.C.-H. Yang and Others
N Engl J Med; Oct 30, 2025; 393(17)：1681-1693
9
A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain
半月板撕裂和膝关节疼痛的物理治疗随机试验
J.N. Katz and Others
N Engl J Med; Oct 30, 2025; 393(17)：1694-1703
10
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine
甲型副伤寒沙门菌疫苗的安全性、有效性和免疫原性
N. McCann and Others
N Engl J Med; Oct 30, 2025; 393(17)：1704-1714
REVIEW ARTICLE（综述）
11
Noninvasive Assessment of Liver Fibrosis
肝脏纤维化的无创评估
L. Castera , M.E. Rinella , and E.A. Tsochatzis
N Engl J Med; Oct 30, 2025; 393(17)：1715-1729
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Herpes Simplex Virus Blepharitis
单纯疱疹病毒性睑缘炎
P. Ros-Arlanzón and M. Alcaraz-Graña
N Engl J Med; Oct 30, 2025; 393(17)：1730
13
Nasal Leech
鼻腔水蛭
W. Wu and J. Tan
N Engl J Med; Oct 30, 2025; 393(17)：e28
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia
病例31-2025：一例56岁男性，左侧下腹部疼痛伴贫血
B.E. Sands and Others
N Engl J Med; Oct 30, 2025; 393(17)：1731-1740
EDITORIALS（社论）
15
Early Detection of Prostate Cancer — Time to Fish or Cut Bait
前列腺癌的早期检测——是时候行动还是放弃
A. Vickers
N Engl J Med; Oct 30, 2025; 393(17)：1742-1743
16
EGFR-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon
EGFR突变型肺癌——破茧成蝶
A. Dimou and A. Mansfield
N Engl J Med; Oct 30, 2025; 393(17)：1743-1745
MEDICINE AND SOCIETY（医学与社论）
17
The Primary Care Puzzle: The Concierge Cure?
初级保健难题：私人医生服务是解决之道吗？
L. Rosenbaum
N Engl J Med; Oct 30, 2025; 393(17)：1746-1750
CORRESPONDENCE（读者来信）
18
Two-Year Outcomes after Transcatheter Arterialization of the Deep Veins
深静脉经导管动脉化两年后的疗效
N Engl J Med; Oct 30, 2025; 393(17)：1751-1753
19
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
非奈利酮联合恩格列净治疗慢性肾脏病和2型糖尿病
N Engl J Med; Oct 30, 2025; 393(17)：1753-1755
20
As-Needed Albuterol–Budesonide in Mild Asthma
按需使用沙丁胺醇-布地奈德治疗轻度哮喘
N Engl J Med; Oct 30, 2025; 393(17)：1755-1756
21
Donor Hearts for Transplantation after Circulatory Death
循环死亡后供体心脏的移植
N Engl J Med; Oct 30, 2025; 393(17)：1756-1760
N Engl J Med[Jour] AND 393[volume] AND 18[issue]
新英格兰医学杂志 393卷18期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: The Antitrust Antidote to Hospital and Nursing Home Corporatization — Promises and Pitfalls
美国医疗保健的企业化：用反垄断法应对医院和养老院企业化——承诺与陷阱
Y. Singh
N Engl J Med; Nov 6, 2025; 393(18)：1761-1764
2
Adverse Health Effects of Energy-Related Provisions in the “One Big Beautiful Bill”
“宏伟美丽法案”中能源相关条款对健康的不利影响
R.L. Glicksman
N Engl J Med; Nov 6, 2025; 393(18)：1764-1766
3
Medicaid Cuts and U.S. Children’s Health — Fixing a Broken System
医疗补助削减与美国儿童健康——修复破碎的体系
E.E. McGinty , A. Bitton , and S.R. Permar
N Engl J Med; Nov 6, 2025; 393(18)：1766-1769
4
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: If You Break It, 未作其他说明——第三季：初级保健的永恒危机：若你将其破坏
They Won’t Come — NOS Episode 3.4
N Engl J Med; Nov 6, 2025; 393(18)：e29
5
Perspective Roundtable: Pursuing Health Equity in the United States
观点圆桌会议：在美国追求健康公平
C.W. Cené and Others
N Engl J Med; Nov 6, 2025; 393(18)：e30
ORIGINAL ARTICLES（论著）
6
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
乳腺癌术后胸壁放疗的十年生存率
I.H. Kunkler and Others
N Engl J Med; Nov 6, 2025; 393(18)：1771-1783
7
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
口服伊可曲金拉治疗成人和青少年斑块状银屑病
R. Bissonnette and Others
N Engl J Med; Nov 6, 2025; 393(18)：1784-1795
8
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
奥福格列隆：一种用于肥胖治疗的口服小分子GLP-1受体激动剂
S. Wharton and Others
N Engl J Med; Nov 6, 2025; 393(18)：1796-1806
9
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
一种rVSV拉沙热候选疫苗的安全性和免疫原性
E. Malkin and Others
N Engl J Med; Nov 6, 2025; 393(18)：1807-1818
10
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
塞瓦伯替尼治疗晚期HER2突变型非小细胞肺癌
X. Le and Others
N Engl J Med; Nov 6, 2025; 393(18)：1819-1832
CLINICAL PRACTICE（临床实践）
11
Opioid Deprescribing in Patients with Noncancer Pain
非癌性疼痛患者的阿片类药物减量
C.-W.C. Lin and A.V. Langford
N Engl J Med; Nov 6, 2025; 393(18)：1833-1842
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Patent Persistent Omphalomesenteric Duct
持续性脐肠管未闭
P.-L. Verot and P.-Y. Rabattu
N Engl J Med; Nov 6, 2025; 393(18)：1843
13
Goiter, Bounding Pulses, and Thyroid Bruit in Thyroid Storm
甲状腺危象中的甲状腺肿、洪脉和甲状腺杂音
T. Yagi and T. Kawasaki
N Engl J Med; Nov 6, 2025; 393(18)：e31
CLINICAL PROBLEM-SOLVING（临床问题解决）
14
Spiraling into a Distant Past
陷入遥远的过去
J. Van den Eynde and Others
N Engl J Med; Nov 6, 2025; 393(18)：1844-1850
EDITORIALS（社论）
15
Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer
乳腺癌乳房切除术后省略胸壁放疗
J. de Boniface
N Engl J Med; Nov 6, 2025; 393(18)：1852-1853
16
Oral Psoriasis Therapy — For Whom and at What Cost and Risk?
口服银屑病疗法——适用于哪些患者，成本和风险如何？
R.S. Stern
N Engl J Med; Nov 6, 2025; 393(18)：1854-1855
CLINICAL DECISIONS（临床决策）
17
Carotid-Artery Stenting or Carotid Endarterectomy for Symptomatic Carotid-Artery Stenosis?
症状性颈动脉狭窄：颈动脉支架置入术还是颈动脉内膜切除术？
S. Gorey , G.J. de Borst , and T.N. Nguyen
N Engl J Med; Nov 6, 2025; 393(18)：1856-1858
CORRESPONDENCE（读者来信）
18
Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys — at 10 Years
已故供体肾脏的冷灌注与静态冷保存——10年对比
N Engl J Med; Nov 6, 2025; 393(18)：1859-1861
19
Vepdegestrant in Advanced Breast Cancer
维培吉司他治疗晚期乳腺癌
N Engl J Med; Nov 6, 2025; 393(18)：1861-1862
20
Testosterone for Middle-Aged and Older Men with Hypogonadism
睾酮治疗中老年男性性腺功能减退症
N Engl J Med; Nov 6, 2025; 393(18)：1863-1864
N Engl J Med[Jour] AND 393[volume] AND 19[issue]
新英格兰医学杂志 393卷19期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Erosion of Harm Reduction
损害减少策略的削弱
J.A. Barocas
N Engl J Med; Nov 13, 2025; 393(19)：1865-1867
2
Religious Liberty as a Shield for Public Health — The Case of Overdose-Prevention Centers
宗教自由作为公共卫生的护盾——过量预防中心案例
B.A. Barsky , A. Caplan-Bricker , and C. Robertson
N Engl J Med; Nov 13, 2025; 393(19)：1867-1869
3
Truly Prioritizing Child Health — The Missed Opportunities of the MAHA Commission
真正将儿童健康置于首位——MAHA委员会错失的机遇
J.M. Perrin and T.L. Cheng
N Engl J Med; Nov 13, 2025; 393(19)：1869-1872
4
What Is Hospice?
什么是临终关怀？
T.D. Brender
N Engl J Med; Nov 13, 2025; 393(19)：1872-1873
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Undervalued — NOS Episode 3.5
未作特别说明——第三季：初级保健的永恒危机：价值被低估——NOS 第 3.5 集
N Engl J Med; Nov 13, 2025; 393(19)：e32
ORIGINAL ARTICLES（论著）
6
Deferring Arterial Catheterization in Critically Ill Patients with Shock
对休克危重患者推迟动脉导管置入术
G. Muller and Others
N Engl J Med; Nov 13, 2025; 393(19)：1875-1888
7
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction
无射血分数降低的心肌梗死后使用β受体阻滞剂
B. Ibanez and Others
N Engl J Med; Nov 13, 2025; 393(19)：1889-1900
8
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure
无心力衰竭的心肌梗死后患者使用β受体阻滞剂
J. Munkhaugen and Others
N Engl J Med; Nov 13, 2025; 393(19)：1901-1911
9
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Sacituzumab Govitecan 用于未经治疗的晚期三阴性乳腺癌
J. Cortés and Others
N Engl J Med; Nov 13, 2025; 393(19)：1912-1925
REVIEW ARTICLE（综述）
10
Acromegaly
肢端肥大症
A. Giustina and A. Colao
N Engl J Med; Nov 13, 2025; 393(19)：1926-1939
IMAGES IN CLINICAL MEDICINE（临床医学影像）
11
Erythema Infectiosum
传染性红斑
J. Martinez-Coronado and R. Salazar
N Engl J Med; Nov 13, 2025; 393(19)：1940
12
Forehead Venous Pulsations in Severe Tricuspid Regurgitation
严重三尖瓣反流患者的额部静脉搏动
E.F. Aleong and Y.S. Chatzizisis
N Engl J Med; Nov 13, 2025; 393(19)：e33
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
13
Case 32-2025: A 79-Year-Old Man with Dyspnea, Edema, and Pacemaker-Lead Displacement
病例 32-2025：一例79 岁男性，出现呼吸困难、水肿和起搏器导线移位
J. Liu and Others
N Engl J Med; Nov 13, 2025; 393(19)：1941-1951
EDITORIAL（社论）
14
A Less Invasive Approach to Intensive Care
重症监护的侵入性较小的治疗方法
H.B. Gershengorn
N Engl J Med; Nov 13, 2025; 393(19)：1953-1954
MEDICINE AND SOCIETY（医学与社会）
15
The Primary Care Puzzle: PCPs, APPs, and the Everything Bagel Problem — Choosing Not to Choose
初级保健难题：初级保健医生、高级实践护士与“全能包”问题——选择不选择
L. Rosenbaum
N Engl J Med; Nov 13, 2025; 393(19)：1955-1959
CORRESPONDENCE（读者来信）
16
A Mammarenavirus Close to Lassa Virus in a Patient with Meningoencephalitis
一名脑膜脑炎患者体内发现与拉沙病毒接近的哺乳动物雷斯顿病毒
N Engl J Med; Nov 13, 2025; 393(19)：1960-1962
17
Acute Normovolemic Hemodilution in Cardiac Surgery
心脏手术中的急性等容性血液稀释
N Engl J Med; Nov 13, 2025; 393(19)：1963-1964
18
Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma
辅助西米普利单抗治疗皮肤鳞状细胞癌
N Engl J Med; Nov 13, 2025; 393(19)：1964-1965
19
Educational Strategies for Clinical Supervision of Artificial Intelligence Use
人工智能使用临床监督的教育策略
N Engl J Med; Nov 13, 2025; 393(19)：1965-1968
N Engl J Med[Jour] AND 393[volume] AND 20[issue]
新英格兰医学杂志 393卷20期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Tobacco Use Reduction: Integration of Tobacco-Cessation Interventions into Tuberculosis and HIV Care
减少烟草使用：将戒烟干预措施纳入结核病和艾滋病护理
J. Shuter , S. Goel , and S.S. Himelhoch
N Engl J Med; Nov 20, 2025; 393(20)：1969-1972
2
Regulating Corporate Control in Health Care — Oregon’s Attempt to Revive the CPOM Doctrine
规范医疗保健中的企业控制——俄勒冈州尝试重振“专业执业组织”原则
J.M. Zhu and H. Rooke-Ley
N Engl J Med; Nov 20, 2025; 393(20)：1972-1974
3
Pistachio Ice Cream
开心果冰淇淋
B.B. Kamdar
N Engl J Med; Nov 20, 2025; 393(20)：1975-1977
ORIGINAL ARTICLES（论著）
4
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias
提高高危室性心律失常患者的血钾水平
C. Jøns and Others
N Engl J Med; Nov 20, 2025; 393(20)：1979-1989
5
Reduction of Antihypertensive Treatment in Nursing Home Residents
减少养老院居民的抗高血压治疗
A. Benetos and Others
N Engl J Med; Nov 20, 2025; 393(20)：1990-2000
6
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
改良信使核糖核酸（mRNA）流感疫苗的有效性、免疫原性和安全性
D. Fitz-Patrick and Others
N Engl J Med; Nov 20, 2025; 393(20)：2001-2011
7
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
Belzutifan治疗晚期嗜铬细胞瘤或副神经节瘤
B. Jimenez and Others
N Engl J Med; Nov 20, 2025; 393(20)：2012-2022
REVIEW ARTICLE（综述）
8
Long QT Syndrome
长QT综合征
P.J. Schwartz and L. Crotti
N Engl J Med; Nov 20, 2025; 393(20)：2023-2034
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Cutaneous Metastases from Breast Carcinoma
乳腺癌的皮肤转移
Y.-H. Hsu and H.-J. Wang
N Engl J Med; Nov 20, 2025; 393(20)：2035
10
Ortner’s Syndrome in Pulmonary Hypertension
肺动脉高压伴发的奥特纳综合征
R. Plácido and B. Baptista
N Engl J Med; Nov 20, 2025; 393(20)：e35
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
11
Case 33-2025: A 27-Year-Old Man with Abnormal Behaviors, Confusion, and Seizure
病例33-2025：一例27岁男性，出现行为异常、意识模糊和癫痫发作
N.V. Quijije and Others
N Engl J Med; Nov 20, 2025; 393(20)：2036-2045
EDITORIALS（社论）
12
Targeting Potassium for Prevention of Ventricular Arrhythmias
以钾为靶点预防室性心律失常
N.A. Chatterjee
N Engl J Med; Nov 20, 2025; 393(20)：2047-2048
13
An Early Look at mRNA Vaccines to Prevent Influenza
预防流感的信使核糖核酸（mRNA）疫苗的早期审视
H.M. El Sahly and R.L. Atmar
N Engl J Med; Nov 20, 2025; 393(20)：2048-2050
CLINICAL DECISIONS（临床决策）
14
To Treat or Not to Treat? Watchful Waiting or Oral Antihypertensives for Asymptomatic Inpatient Hypertension
治疗还是不治疗？无症状住院高血压患者的观察等待或口服抗高血压药物选择
S. Gorey , M. Rothberg , and T.I.-H. Chang
N Engl J Med; Nov 20, 2025; 393(20)：2051-2053
CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义）
15
A New Stage for Seasoned Actors — Food Anaphylaxis and the Cysteinyl Leukotrienes
资深“演员”的新舞台——食物过敏性休克与半胱氨酰白三烯
J.A. Boyce
N Engl J Med; Nov 20, 2025; 393(20)：2054-2057
MEDICINE AND SOCIETY（医学与社会）
16
The Primary Care Puzzle: Why Have We Chosen Not to Fix Primary Care? The Vicious Cycle of Medical Hierarchy
初级保健难题：我们为何选择不修复初级保健？医疗等级制度的恶性循环
L. Rosenbaum
N Engl J Med; Nov 20, 2025; 393(20)：2058-2062
CORRESPONDENCE（读者来信）
17Toward Same-Day Genome Sequencing in the Critical Care Setting
在重症监护环境中实现当日基因组测序
N Engl J Med; Nov 20, 2025; 393(20)：2063-2065
18
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Cagrilintide-Semaglutide治疗超重或肥胖成人
N Engl J Med; Nov 20, 2025; 393(20)：2065-2068
19
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
新辅助纳武利尤单抗联合化疗治疗肺癌
N Engl J Med; Nov 20, 2025; 393(20)：2068-2070
20
Pathogenesis of Heparin-Induced Thrombocytopenia
肝素诱导的血小板减少症的发病机制
N Engl J Med; Nov 20, 2025; 393(20)：2070-2071
2025-11-20
·网易号
来源：瞭望智库当全球进入“人工智能+”时代，医疗健康这一最为复杂、最关乎人类福祉的领域，正站在数字化转型的爆发前夜。在这幅宏大的图景中，跨国药企扮演着什么角色？是旁观者、参与者，还是引领者？作为最早扎根中国的跨国药企之一，罗氏制药用行动给出了答案。在第八届中国国际进口博览会现场，罗氏制药中国总裁边欣表示，罗氏正“从肿瘤与特药领域的专科引领者，加速向全疾病领域综合领航者跨越”。这一跨越，仅靠单一的药物创新远远不够，还需要以AI为核心的智慧医疗生态建设。这家明年即将迎来在华百年的企业，不仅以其庞大的创新药管线令人瞩目，更希望在中国描绘出一幅更具韧性、更富效率的未来医疗图景。1生态共建：从“单兵突进”到“集团军作战”在传统的认知里，药企的核心是研发与销售。但罗氏制药勾勒了一幅截然不同的画面——在人工智能的时代下，医院通过建设更强的数字化人工智能能力，在患者的筛查、诊疗和长期管理上能够带来巨大价值。这需要从整个生态体系的视角去看医院的数字化发展。这个“生态视角”，是罗氏破局智慧医疗的关键密钥。罗氏清醒地认识到，医疗AI的复杂性绝非任何一家企业能够独力承担。因此，罗氏选择了一种“集团军作战”的模式，主动携手中国信息通信研究院这类“国家队”科研机构，联合41家头部公立医院，以及众多科技企业与通信运营商，共同编织一张智慧医疗的协同网络。行业标准扮演了一个很重要的角色，能够帮行业中所有的医务工作者、科技企业和一系列的创新者去了解数智医疗，推动其在整个交叉学科当中更好地实现价值。这是罗氏实践生态共建的核心成果之一。今年，这个“生态联盟”共同建设了两项数字医疗行业标准，这如同为飞速发展的行业铺设了铁轨，避免了“各自为政”的混乱，让创新列车能够沿着规范、高效的路径疾驰。而更具象的成果，则体现在一个个专科“样板间”里。在肿瘤、罕见病等垂直领域，罗氏将自身深厚的临床知识沉淀为“燃料”，注入合作伙伴的AI技术“引擎”，共同打造出融合了顶尖医学智慧与算法模型的数字化解决方案。这一探索的价值在实战中得到了检验——在工业和信息化部指导的算力应用大赛中，罗氏与合作医院的参赛项目荣获了多个奖项，这无疑是其生态战略有效性的最强证明。2攻坚克难：直面智慧医疗的“三座大山”尽管前景广阔，但前路并非坦途。罗氏在实践中也遇到了“三座大山”：医疗数据的整合与透明共享、行业标准的空白与欠缺，以及AI技术在医患群体中的认知与使用普及。首先，数据是AI的“粮食”。但在中国庞大而复杂的医疗体系下，数据孤岛现象普遍存在。对此，罗氏正积极探索“医疗数据可信空间”的构建。这是一种在严格保障数据安全与隐私的前提下，实现数据“可用不可见”的技术路径。它如同一个安全的“数据保险库”，各方可以在此进行联合建模与分析，却拿不走原始数据，从而为跨医院的科研协作和患者全程管理服务提供了可能。其次，针对标准空白这一挑战，罗氏选择主动出击。除了今年已完成的两项标准，明年罗氏还有更大的计划——在专科和医疗系统去做更多数字医疗领域行业标准建设的工作。这种“先行者”的姿态，正是其长期主义理念的体现。最后，如何让技术从“高阁”走向“床边”，是AI价值最终实现的临门一脚。罗氏的解法是“场景化落地”：通过一系列患者管理平台的推广，将AI融入患者的日常疾病管理；通过AI赋能的疾病教育方案，提升大众的健康素养；甚至运用AI数字人技术，革新传统的导医导诊服务，提升就医体验。这一切的努力，都是为了让人工智能变得可感、可知、可用，真正惠及千家万户。3双轮驱动：创新药与数字化比翼齐飞或许有人会问，一家以创新药立身的公司，为何要涉足数字化？答案在于罗氏对未来医疗的深刻洞察。正如罗氏制药中国总裁边欣所说，罗氏要“从肿瘤与特药领域的专科引领者，加速向全疾病领域综合领航者跨越”。仅靠单一的药物创新，远远不够实现这一战略。罗氏有着“双轮驱动”战略：一个轮子是持续推出引领全球的创新药物。从在狼疮性肾炎中显示出积极结果的佳罗华®，到全球首个眼内植入物PDS给药系统，再到覆盖阿尔茨海默病、帕金森病、代谢性疾病的十余款重磅在研管线，罗氏的研发引擎依然强劲。另一个轮子便是以AI为核心的智慧医疗生态建设。药物解决的是“治疗”的问题，而数字化解决方案则贯穿于“预防、诊断、治疗、康复”的全生命周期。两者相辅相成：创新药为数字化方案提供了专业的医学基础和精准的干预靶点；而数字化工具则能提升罗氏药物的可及性及使用罗氏药物患者的依从性，并生成真实的临床数据反哺科研。明年，罗氏将迎来在华100周年。这家企业正以实际行动诠释其长期承诺——投资超20亿元人民币在上海新建生物制药生产基地，强化本土化供应链；同时，在数字医疗这片新蓝海中的持续投入，则彰显了其与中国医疗体系共同进化、共赢未来的智慧与决心。在人工智能与医疗健康深度融合的浪潮中，罗氏制药正以其深厚的医学积淀、开放的生态合作和前瞻的数字布局，悄然执笔，致力于描绘一幅更智能、更高效、也更温暖的中国未来医疗图景。这条路虽漫长，但方向已然清晰。
100 项与 奥妥珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 狼疮性肾炎 | 美国 | 2025-10-17 | |
| CD20阳性B细胞慢性淋巴细胞白血病 | 日本 | 2022-12-23 | |
| CD20阳性滤泡性淋巴瘤 | 日本 | 2018-07-02 | |
| CD20阳性滤泡性淋巴瘤 | 日本 | 2018-07-02 | |
| 滤泡性淋巴瘤 | 澳大利亚 | 2014-05-15 | |
| 慢性淋巴细胞白血病 | 美国 | 2013-11-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 边缘区B细胞淋巴瘤 | 申请上市 | 中国 | 2019-09-28 | |
| 膜性肾小球肾炎 | 临床3期 | 荷兰 | - | 2025-10-01 |
| 肿瘤溶解综合征 | 临床3期 | 美国 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 澳大利亚 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 法国 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 希腊 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 塞尔维亚 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 西班牙 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 中国台湾 | 2024-08-05 | |
| 肿瘤溶解综合征 | 临床3期 | 英国 | 2024-08-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 271 | (Obinutuzumab) | 窪膚鬱製繭窪鹹壓鏇壓 = 蓋鏇醖艱觸築襯繭觸醖 廠糧選醖衊鏇鹽獵壓鹽 (願製鹹觸壓網餘選醖網, 襯糧觸糧衊築顧築窪鏇 ~ 鹹糧憲簾積獵壓淵膚廠) 更多 | - | 2025-11-06 | ||
(Placebo) | 窪膚鬱製繭窪鹹壓鏇壓 = 齋淵淵醖憲蓋鹽鏇顧觸 廠糧選醖衊鏇鹽獵壓鹽 (願製鹹觸壓網餘選醖網, 淵構製鹹鏇選網簾繭獵 ~ 選製簾願襯網蓋構願膚) 更多 | ||||||
临床3期 | - | Gazyva/Gazyvaro + standard therapy | 範膚醖壓鹹鹹願齋襯鏇(艱糧糧蓋糧廠壓鏇願襯) = 膚膚壓膚膚築築築築憲 願鏇醖鹽觸窪鏇齋襯艱 (襯觸鹽壓顧選積餘窪觸 ) 达到 更多 | 积极 | 2025-11-03 | ||
Placebo + standard therapy | 積鹹繭鏇廠蓋淵鬱觸鑰(繭蓋積網壓餘簾遞艱衊) = 衊簾夢鹹艱淵顧選衊選 築簾築鏇顧選製繭網選 (鑰構壓艱鑰鹹顧蓋製築 ) 达到 更多 | ||||||
临床3期 | 85 | 範壓膚鬱夢選願獵範糧(糧壓鑰鑰鏇範窪遞窪鬱) = more people achieving sustained complete remission with Gazyva/Gazyvaro compared with mycophenolate mofetil (MMF) 餘夢鬱鬱顧襯願構觸網 (艱鹽積範遞鑰積鹹鑰鬱 ) 达到 更多 | 积极 | 2025-10-28 | |||
临床3期 | 271 | Obinutuzumab+Standard Therapy | 醖壓鏇鬱鏇淵廠餘鬱鬱(製願構製衊鬱獵積鏇淵) = 廠鹽積廠鹹繭鬱範鹹選 鏇鑰顧糧淵糧襯鏇憲顧 (鹽艱淵鑰觸構夢鹽夢鹹 ) 更多 | 积极 | 2025-10-24 | ||
Placebo+Standard Therapy | 醖壓鏇鬱鏇淵廠餘鬱鬱(製願構製衊鬱獵積鏇淵) = 鹽糧顧窪顧顧餘構積淵 鏇鑰顧糧淵糧襯鏇憲顧 (鹽艱淵鑰觸構夢鹽夢鹹 ) 更多 | ||||||
临床3期 | 286 | Obinutuzumab plus standard therapy | 鏇餘範齋鏇衊積鬱積遞(夢醖鬱鑰齋觸鹽夢簾積) = 廠選製鏇壓壓夢夢選襯 衊憲衊鹽構淵膚醖鏇艱 (願憲獵醖積範齋憲憲鑰, 45.6) 更多 | 积极 | 2025-10-24 | ||
Placebo plus standard therapy | 鏇餘範齋鏇衊積鬱積遞(夢醖鬱鑰齋觸鹽夢簾積) = 蓋蓋範鹽簾蓋鑰鹽製鬱 衊憲衊鹽構淵膚醖鏇艱 (願憲獵醖積範齋憲憲鑰, 338.5) 更多 | ||||||
N/A | 抗中性粒细胞胞质抗体相关性血管炎 PR3+ | 5 | 餘築醖餘窪淵選鏇簾壓(壓醖顧夢壓糧餘餘艱齋) = Obinutuzumab was effective in inducing and maintaining disease remission. Those patients with detectable ANCA titres at time of obinutuzumab treatment seroconverted from positive to negative. 蓋淵積廠製廠夢壓構糧 (膚選蓋鏇糧糧齋膚鬱願 ) 更多 | 积极 | 2025-10-24 | ||
临床3期 | 328 | 艱網夢製鑰艱鬱觸膚獵(製範範鏇衊範選膚蓋糧) = 夢衊網遞夢選襯遞夢襯 網觸積選艱淵鑰範遞願 (積築繭齋糧鑰鏇醖鹽鹹 ) 更多 | 积极 | 2025-10-24 | |||
艱網夢製鑰艱鬱觸膚獵(製範範鏇衊範選膚蓋糧) = 糧簾選顧窪積構網鏇壓 網觸積選艱淵鑰範遞願 (積築繭齋糧鑰鏇醖鹽鹹 ) 更多 | |||||||
临床3期 | 136 | Obinutuzumab+Standard Therapy | 艱觸淵築襯醖蓋網遞積(選衊獵顧鹹願觸蓋構網) = 簾蓋廠願夢鹽構餘鹹鬱 糧鏇願觸淵繭窪範簾築 (構夢壓繭鬱醖憲選願積 ) 更多 | 积极 | 2025-10-24 | ||
Placebo+Standard Therapy | 艱觸淵築襯醖蓋網遞積(鹹鹽網網觸觸簾鹹糧齋) = 衊選齋製壓夢觸夢餘網 構繭網願願窪鬱繭鬱製 (襯簾醖窪壓獵鬱獵醖夢 ) 更多 | ||||||
临床2期 | 狼疮性肾炎 IFN-I | 126 | 齋製鑰壓鬱鹽淵願廠壓(構膚廠製構蓋鑰積餘築) = 衊餘襯積簾鹽觸餘艱襯 製繭鹹醖窪衊遞壓壓鏇 (鑰壓壓齋廠鹽壓鑰廠餘 ) | 积极 | 2025-10-24 | ||
Placebo | 齋製鑰壓鬱鹽淵願廠壓(構膚廠製構蓋鑰積餘築) = 壓餘範鹽簾蓋窪窪鏇製 製繭鹹醖窪衊遞壓壓鏇 (鑰壓壓齋廠鹽壓鑰廠餘 ) | ||||||
临床1/2期 | 32 | 窪壓壓鑰遞積壓淵衊積 = 網觸鹹選築廠糧鹽願鬱 構艱鑰鹹夢鹹壓遞鹽醖 (艱廠觸積襯鏇艱積觸遞, 餘艱窪齋憲觸淵鏇衊齋 ~ 齋壓積齋構鏇繭窪繭鹽) 更多 | - | 2025-09-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用